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1. INTRODUCTION AND JUSTIFICATION 
Hepatitis B infection which has been listed among the top ten leading causes of death 
worldwide is one of the few vaccine preventable causes of a cancer(1). It is estimated 
that one in three persons worldwide show evidence of current or past infection with 
Hepatitis B. There are around 350 million chronic carriers of Hepatitis B infection of 
which a fourth will progress to have either cirrhosis of the liver or hepatocellular 
carcinoma(2). 
Although there are many approaches to prevent transmission of Hepatitis B infection, 
Hepatitis B vaccine is the most effective method for the same. The vaccine has an 
efficacy of 95% when used as a pre-exposure prophylaxis (3). 
Perinatal transmission of Hepatitis B which is an important route of infection is 
believed to be responsible for a third of adult chronic carriers in India (4,5). Prevention of 
perinatal transmission of Hepatitis B is an effective method of reducing the prevalence 
of chronic HBsAg carriers, in areas where a large proportion have acquired infection 
through this route. Studies have shown that a combination of Hepatitis B 
immunoglobulin and Hepatitis B vaccine is 92-100% effective in preventing perinatal 
transmission of Hepatitis B from HBsAg positive mothers to their infants (6). However, 
in view of the high costs of Hepatitis B immunoglobulin, this strategy may not be 
possible in resource poor countries like India. The Hepatitis B vaccine alone when 
given soon after birth also has a remarkable efficacy ranging from 72%-100%, when 
given as a post exposure prophylaxis to infants born to HBsAg positive mothers (6,7).  
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One strategy followed at national levels is universal immunization of all infants. When 
this scheme involves routine administration of the first dose of vaccine within 24 hours, 
it is the ideal way to prevent both vertical and horizontal transmission. The other 
strategy involves screening of all pregnant women during the antenatal period and 
selectively immunizing the infants born to the HBsAg positive mothers. Although 
universal immunization may be more cost effective in the long run it is not feasible in 
places where the rate of institutional deliveries is low (8). Thus the selective 
immunization strategy is an option in places where resources are limited and the 
prevalence of Hepatitis B is also very low.  
In India the Hepatitis B immunization program which was initially introduced as a pilot 
project, followed a schedule of immunization at 6, 10 and 14 weeks along with the three 
DPT immunizations, with the aim to prevent early horizontal transmission (9). The 
effectiveness of this strategy has not been studied to prove lower transmission of 
Hepatitis B in the pilot areas. 
It has been argued that it is very difficult to routinely screen all pregnant women, offer 
counseling services for test positive women and ensure delivery of the birth dose of 
vaccine for these women. The Community Health Department of Christian Medical 
College has been providing such a screening program for antenatal women through 
services at the village level as well as at the base hospital, since 2002. Children born to 
mothers who tested positive for HBsAg were offered immunization commencing at 
birth, in order to prevent perinatal transmission. This study was an evaluation of the 
effectiveness of this program of antenatal screening and selective immunization of the 
infants born to HBsAg positive mothers. 
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2. AIMS AND OBJECTIVES 
Aim: 
To evaluate a program to prevent vertical transmission of Hepatitis B in Kaniyambadi 
block and CHAD hospital 
Primary objective: 
To evaluate the effectiveness of the program in reducing the vertical transmission of 
Hepatitis B among children born to HBsAg positive mothers who received three doses 
of the Hepatitis B vaccine commencing at birth 
Secondary objectives: 
1. To assess the effectiveness of the Hepatitis B immunization program in 
providing the planned immunization schedule commencing at birth 
2. To determine seroprotection among children who received three doses of the 
Hepatitis B vaccine 
3. To determine the prevalence of HBsAg among children born to HBeAg positive 
mothers, who received three doses of Hepatitis B vaccine commencing at birth 
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                             3. REVIEW OF LITERATURE 
3.1 The Magnitude of the problem of Hepatitis B infection  
The World Health Organization (WHO) estimates that two billion people worldwide 
have serologic evidence of past or current infection with Hepatitis B. The number of 
chronic carriers who are test positive for Hepatitis B surface antigen (HBsAg) for a 
period of at least 6 months is around 350 million. Every year, globally, around 600,000 
people die of Hepatitis B related diseases such as cirrhosis of the liver and 
hepatocellular carcinoma (10). 
The epidemiology of Hepatitis B virus infection has been described according to three 
categories of high, intermediate and low endemicity. Countries with high endemicity 
are those where HBsAg seroprevalence rate is 8% or more; countries with intermediate 
endemicity are those with seroprevalence of 2-7%; and those with low endemicity are 
those with seroprevalence of less than 2 %(11). Regions with high endemicity include 
South-East Asia, China and the Amazon basin while regions with intermediate 
endemicity are parts of Eastern and Southern Europe, the Middle East, Japan and parts 
of South America. Developed countries in Northern America, Western and Northern 
Europe and Australia have low endemicity (12). 
3.2 Prevalence of Hepatitis B carriers in India 
Indian studies show wide variations in the prevalence of Hepatitis B surface antigen 
positivity based on whether they were done among antenatal women, blood donors 
(voluntary, replacement or professional donors), children, general population, groups at 
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high risk for sexually transmitted infections, tribal populations etc. For a long time it 
was believed that the national average carrier rate was 4.7% according to the consensus 
statement of the Indian Association for the Study of the Liver (INASL). India was said 
to be an intermediate prevalence country for chronic carriers of Hepatitis B. One of the 
flaws with this estimate was that all the studies were one time cross sectional surveys of 
prevalence of Hepatitis B infection and not of the chronic carrier rate, which would 
have required a second test to be positive after 6 months. Many of the studies included 
individuals belonging to high risk groups which have a higher prevalence compared to 
the general population. Another limitation was that the estimate of test positivity of 
4.7% was not a weighted average, but a simple average of the prevalence in different 
studies (13).  
There are very few estimates of prevalence of HBsAg infection in India from 
community based surveys. A community cluster study done in Tamil Nadu, estimated 
that the prevalence of Hepatitis B infection was 5.7% (95% CI: 4.7%-6.8%) in the 
general population (14). However it was later found that the area in which the study was 
carried out was a zone with a high prevalence of commercial sex workers. A 
community based study done among women in the reproductive age group in an urban 
slum of migrant workers in Delhi, showed a prevalence of 5.8%. This study showed 
increasing prevalence with age, as the prevalence was 9.7% among older women (more 
than 30 years) as compared to 3.1% among younger women (15-29 years) (15). Another 
community based study of the prevalence of reproductive tract infections among young 
married women, showed a prevalence of 2% for Hepatitis B surface antigen in 
Kaniyambadi block, Tamil Nadu (16). 
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A review done by Anant Phadke et al using data from 19 studies, excluding those from 
high risk groups, stated that the prevalence of chronic carriers of Hepatitis B was 1.42% 
challenging the previously accepted figure of 4.7% (13). Further a systematic review of 
literature by Lodha et al in 2001, estimated the prevalence of Hepatitis B positive 
carriers to be between 1 to 2 %  which also suggested that India was a low prevalence 
country (17).  
In 2007 a meta-analysis done under the guidance of the Indian Medical Association was 
published as an improvement over the systematic review done by Lodha et al. This 
study showed that the true prevalence of Hepatitis B was 2.4 % (95% CI: 2.2%-2.7%) 
in non-tribal populations and 15.9 % (95% CI: 11.4%-20.4%) in tribal populations.  
Assuming that 80% of those who are test positive for HBsAg will continue to be test 
positive after 6 months of the initial test, the prevalence of chronic carriers among non 
tribal populations was 1.9% according to this meta-analysis(18). This was consistent with 
the earlier finding of the systematic review by Lodha et al.  
The prevalence of HBeAg is highly variable among different populations. According to 
the review by Lodha R et al, the HBeAg positivity rate among chronic carriers of 
Hepatitis B surface antigen was 7.8-47.8%, with most studies showing 18% or less(17).  
3.3 Hepatitis B virus structure and serology 
The Hepatitis B virus is a DNA virus with an outer lipoprotein envelope containing the 
‘surface antigen' protein (HBsAg) and a nucleocapsid core (Hepatitis B core antigen). 
The nucleocapsid core also includes the viral DNA genome and enzymes. There is 
another protein which is found independently as a soluble antigen secreted from 
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infected cells, called the Hepatitis B e Antigen (HBeAg) whose function is largely 
unknown but which serves as a marker of active viral replication. The persistence of 
HBeAg beyond a period of 10 weeks indicates chronic infection and infectiousness. 
HBV DNA which can be detected by hybridization assays or Polymerase chain reaction 
(PCR), is used to detect mutant forms of the virus which escape detection by 
conventional methods(2). 
The antibodies associated with HBV infection include antibody to HBsAg (anti-HBs), 
antibody to HBcAg (anti-HBc) and antibody to HBeAg (anti-HBe). In persons who 
recover from HBV infection, HBsAg is eliminated from the blood, usually within 3-4 
months, and anti-HBs develops during convalescence. The presence of anti-HBs 
indicates immunity from HBV infection. The majority of persons who recover from 
natural infection will be positive for both anti-HBs and anti-HBc IgG, whereas persons 
who respond to immunization have only anti-HBs. Anti HBs levels of more than or 
equal to10 mIU/ ml, tested 1-3 months after the primary vaccine series is considered to 
be indicative of adequate seroconversion (also called seroprotection). In persons who 
become chronically infected, HBsAg and anti-HBc IgG persist for more than 6 months 
and typically for life (19).  
3.4 Transmission of Hepatitis B  
Hepatitis B is transmitted through perinatal transmission, household (non-sexual) 
contact, sexual contact, blood transfusions, needle sharing and occupation/health-care 
related events. The routes of transmission depend upon the endemicity of HBsAg in the 
region. In high prevalence areas, transmission is mainly perinatal and horizontal 
(exposure to chronically infected household members). In low endemicity areas, it is 
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mostly among young adults who acquire the infection sexually or by injection drug use. 
In intermediate endemicity countries like India, there is a mix of perinatal, health-care 
related, sexual and horizontal routes of transmission but  relative contributions of 
perinatal, sexual and horizontal transmission in childhood are not known(17). 
3.4.1 Perinatal transmission of Hepatitis B  
Perinatal transmission is believed to account for 35-50 % of Hepatitis B carriers in high 
endemicity countries(20). Although there is no definite estimate for India, some studies 
have estimated the proportion of chronic carriers who have acquired the infection 
vertically to be around 33% (4,5). It has been suggested that since there was no 
progressive increase in prevalence of chronic carriers among children, it was unlikely 
that horizontal transmission played a major role in India. (21-23). However, perinatal 
transmission may be responsible for up to 15% HBV related deaths even in low 
endemicity areas(3). 
Studies done in the 1970s first suggested a link between the presence of HBeAg among 
carrier mothers which led to higher transmission of HBsAg to their children (24). A 
study done by Beasley et al in Taiwan found that 85% of children born to HBeAg 
positive mothers were HBsAg positive, compared to 31% of children born to HBeAg 
negative mothers. Further studies done later also confirmed the findings that if the 
mother was both HBsAg and HBeAg positive, 70-90% of the children become 
chronically infected(25-27). If the mother was HBsAg positive but HBeAg negative the 
risk of perinatal infection was only 5-20%(25). The overall risk of acquiring infection 
through this route was 18.6-50% depending on the proportion of HBeAg positive 
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mothers (5). Another risk factor found to be associated with perinatal transmission was 
high levels of HBV DNA in the mothers (28). 
The possible routes for perinatal transmission are trans-placental (intra-uterine) 
infection and transmission at the time of delivery. It has been found that the time of 
acquiring Hepatitis B infection from the infected mothers is more often at birth rather 
than during pregnancy, in-utero transmission accounting for less than 2% of all 
perinatal transmission (25,26). Hepatitis B vaccine and immunoglobulin cannot protect 
against trans-placentally acquired infection which occurs in-utero, which can be 
detected by the presence of IgM anti HBc antibodies in the cord blood. One of the 
suggested mechanisms for trans-placental infection was hematogenous transfer of 
infection when there is some factor like a threatened abortion which causes a break in 
the placental microvasculature. The other route could be cellular transfer, when the 
placenta is infected because of a high titre of the virus in the maternal blood which 
enters the fetal circulation (12). 
There is no clear evidence to suggest that breast feeding increased the risk of acquiring 
HBV infection from HBsAg positive mothers (29,30).  
3.4.2 Horizontal transmission 
Horizontal transmission or early childhood transmission can also occur among children 
through exposure to infected family members or contacts through cuts, bruises, bites etc 
(25). 
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3.5 Morbidity and mortality due to Hepatitis B infection 
Hepatitis B viral infection can lead to acute Hepatitis, chronic HBV infection, cirrhosis 
of the liver or hepatocellular carcinoma. While acute infection is more likely with 
increasing age, the chances of infection remaining chronic are greater among infants.  
The proportion of affected persons who develop signs of acute infection are 1% among 
those affected perinatally, 5-15% among those affected between 1-5 years and 20-50% 
among those affected after 5 years of age. The proportion of infections which become 
chronic is 90% among those affected through vertical transmission; 25-50% among 
those affected between 1-5 years and 6% among those infected later (25).  
There are three phases of chronic Hepatitis B when infection is acquired perinatally. 
The first is an immunotolerant phase when there is a lack of immune response owing to 
tolerance to the virus. There are either mild symptoms or none at all despite a high level 
of viremia. In the second immune clearance phase, clinical remission occurs with 
clearance of the virus due to activation of the immune response. In the residual phase 
there is minimal viral and immunological activity. Cirrhosis of the liver can occur due 
to damage occurring in the immune clearance phase and hepatocellular carcinoma can 
occur even when there is apparent clearance of the virus (31). 
The association between Hepatitis B infection and hepatocellular carcinoma was proved 
by several case-control and prospective studies in Taiwan and China (12,32). Around 25% 
of those who acquire chronic HBV infection die of cirrhosis of the liver or 
hepatocellular carcinoma and 1% clear the virus every year (3) 
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In India, according to the National Cancer Registry Program of the Indian Council of 
Medical Research, there are 5000 deaths every year due to hepatocellular carcinoma 
associated with Hepatitis B, constituting 1.6% of all cancers in India. There are 
undoubtedly many more cases of cirrhosis, but there is no registry maintained for the 
same (33).  
3.5.1 Economic burden of Hepatitis B 
Hepatitis B infection causes ill health through acute hepatitis B, liver cancer or cirrhosis 
of the liver. Assuming that the life expectancy in India in 2040 when future benefits of 
immunization are expected, will be 66 years, and that hepatocellular carcinoma (HCC) 
occurs at 45 years, 21 years of life are lost per case (34). 
A South Korean study estimated that the annual cost of treatment and prevention of 
Hepatitis B was USD 1 billion. The direct medical costs of treatment accounted for 65.9 
% of the total cost, indirect costs for 20.9% and preventive strategies for 13.2% of the 
total cost. Indirect costs included transportation, loss of wages, reduced work 
productivity, and premature death. The mean duration of hospitalization per year was 
15.25 days for acute hepatitis, 16.73 days for chronic hepatitis, 33.83 days for cirrhosis, 
and 38.84 days for liver cancer (35).  
3.6 Prevention of transmission of Hepatitis B 
3.6.1 Prevention of sexual and horizontal transmission 
In countries with low endemicity of infection where the majority of chronic carriers 
acquire infection through sexual contact or injection drug abuse, counseling and 
behavior change communication will be useful in reducing transmission. Screening 
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blood and blood products for HIV, Hepatitis C antibody and Hepatitis B surface antigen 
as well as observing universal precautions in the practice of healthcare are other 
methods used to prevent transmission. 
 
3.6.2 Prevention of perinatal transmission of Hepatitis B 
3.6.2.1 Elective Caesarean section 
In view of the conflicting evidence regarding effectiveness of elective caesarean section 
as a measure to reduce perinatal transmission of Hepatitis B, a recent systematic review 
was conducted to analyze the evidence from randomized controlled trials. It was found 
that elective caesarian section before rupture of membranes reduced the risk of perinatal 
transmission of Hepatitis B. However the trials included in this meta analysis had high 
possibilities for bias and therefore there was no convincing evidence that caesarian 
section should be routinely recommended to reduce perinatal transmission of Hepatitis 
B (36). 
3.6.2.2 Active and Passive Immunization 
Although safe injection practices and promotion of safe sex are important in reducing 
transmission, universal immunization of newborns commencing at birth is considered to 
be the most effective strategy in reducing the prevalence and transmission of Hepatitis 
B. The Hepatitis B vaccine available from 1982 is the world’s first cancer prevention 
vaccine and the first vaccine against a sexually transmitted disease.  
There are two types of vaccine, the plasma derived and recombinant DNA vaccines. 
The recombinant DNA vaccines which are either yeast derived or mammalian cell 
derived have largely replaced the plasma derived vaccines. India has developed an 
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indigenous yeast derived recombinant vaccine called Shanvac-B (Santha Biotechnics, 
1997). Both the plasma derived and recombinant vaccines have similar effectiveness 
and withstand temperatures of up to 45 degrees Celsius for a week and 37 degree 
Celsius for a month (7,37). The vaccine must be stored at 2-8 C but never frozen as 
freezing destroys the potency of the vaccine by dissociation of the antigen from the 
adjuvant alum. 
Prevention of perinatally transmitted infection from Hepatitis B surface antigen positive 
mothers depends on whether the carrier mother is HBeAg positive or not. Infants born 
to mothers who are both HBsAg and HBeAg positive are advised to be given both 
Hepatitis B immunoglobulin and active immunization within 12-24 hours (19). This is 
followed by two more doses commencing at least a month after the first dose. The third 
dose acts as a booster which increases anti HBs to several times above the protective 
level of 10 mIU/ml. Various studies have demonstrated seroprotection rates at one year 
after immunization, to range from 58.8% to 95 % (38,39). 
The Hepatitis B vaccine without Hepatitis B immunoglobulin (HBIG) has also been 
found to be very effective in preventing perinatal infection, when given within 24 hours 
of birth. A randomized double blind controlled trial was done by Beasley et al in 
Taiwan which showed a vaccine efficacy of 75% when the vaccine was used alone to 
prevent perinatal transmission, which was also seen in an Indian study in Delhi (26) , (5). 
Further randomized trials of administration of the Hepatitis B vaccine in a 3 or 4 dose 
schedule without HBIG, beginning within 12 hours after birth, have demonstrated 
prevention of 70%-95% of perinatal HBV infections among infants born to women who 
are positive for both HBsAg and HBeAg (38). A systematic review showed that 
14 
 
protective effect of recombinant DNA vaccines when used without HBIG was 90-100% 
and when used with HBIG was 92%-100%(6). Based on this, it was concluded that 
vaccine alone may be used in national immunization programs, at the meeting of the 
Viral Hepatitis Prevention Board organized in conjunction with CDC/Atlanta, the WHO 
and UNICEF(25). 
A review done by the Cochrane Collaboration showed a vaccine efficacy of 72% (RR 
0.28 95% CI: 0.20-0.40) when the Hepatitis B vaccine was given alone at birth, to 
infants born to HBeAg positive mothers. Subgroup analyses did not find a difference 
based on the mother’s HBeAg status or time of vaccine administration (within 12, 24 or 
48 hours of birth) (7). The use of the vaccine alone is especially important in areas where 
cost makes the use of hepatitis B immune globulin impractical. 
3.7 Immunization schedules for Hepatitis B vaccine 
The Hepatitis B vaccine can be given in different schedules as shown in Table No 1. 
The WHO classifies the various schedules as those having a birth dose and those not 
having one.  
Table No.1 Immunization schedules for Hepatitis B immunization 
Organization with birth dose without birth dose 
WHO, IAP birth, 6 and 14 weeks 6, 10 and 14 weeks 
  birth, 6, 10 and 14 weeks 
ACIP 
birth, 1-2 months, 24 
weeks 
IAP birth, 1 and 6 months   
UIP, India not recommended 6, 10 and 14 weeks 
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Universal immunization at birth is recommended by the WHO, for areas with high 
endemicity or with high chances of perinatal transmission. In this situation the first dose 
must be given as soon as possible after birth (within 24 hours), followed by a second 
dose at 6 and another at 14 weeks. The other schedule is a birth dose followed by three 
doses along with the three DPT doses. Although some studies do show added benefit 
with Hepatitis B immunoglobulin, on operational and cost-effectiveness grounds, the 
WHO does not recommend HBIG in places where there is no antenatal screening for 
HBsAg. When there is no administration of the birth dose the three doses of the vaccine 
may be given at 6, 10 and 14 weeks (3). 
Both the Indian Academy of Pediatrics (IAP) and the Advisory Committee on 
Immunization Practices (ACIP) which provides guidance to the Centers for Disease 
Control and Prevention (CDC) recommend screening of all antenatal women for 
HBsAg in each pregnancy. This is to be followed by administration of Hepatitis B 
vaccine and Hepatitis B Immunoglobulin within 12-24 hours of birth to the infants born 
to the infected mothers. The IAP also recommends routine immunization of all infants 
at birth ,6 and 14 weeks or birth,1 and 6 months. In case the mother is HBsAg negative 
or the birth dose has been missed for some reason, it is recommended to give the three 
doses at 6, 10 and 14 weeks(40).  
3.8 National Policy on Hepatitis B vaccine 
In any country there are different reasons for choosing immunization schedules. These 
include data on magnitude, mortality, mortality which in turn depends on adequate 
disease surveillance mechanisms and judgments regarding incidence levels which 
qualify for commencement of mass immunization programs. Other factors to be 
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considered are immunological appropriateness of the strategy, economical viability and 
technical feasibility. There is also the choice of giving the vaccine to selected high risk 
groups or providing it as part of the Universal Immunization Program (UIP) to all 
children. (41) 
The Government of India launched a pilot project for the introduction of Hepatitis B in 
a phased manner throughout the country, beginning with 15 selected cities and 32 
districts in 17 states in 2002. In this program it was decided to give the Hepatitis B 
vaccine starting at 6 weeks along with DPT, to children living in slums in areas having 
at least 80% coverage for the third dose of DPT, under the UIP (9). Studies have shown 
that such accelerated schedules of 0, 1, 2 months starting at 6 weeks achieved high 
seroconversion although mean GMT was lower compared to schedules of 0, 1, 6 
months and 2, 4, 6 months(42-45). According to the government, Hepatitis B vaccine 
coverage was 69% in 2007 in these project areas. However since the program does not 
insist upon the birth dose and instead gives the  vaccine at 6, 10 and 14 weeks it will not 
be able to tackle the problem of perinatal transmission.  
A sub-committee on immunization formed by the Indian Medical Association evaluated 
the status of the pilot project and reported that there was inadequate evidence of success 
of the pilot project in bringing down the carrier rates in the project areas. Although it 
was planned to conduct a serological survey of 3-5 year olds, 5 years after the 
implementation of the program, there are no reports available of any final evaluation of 
the prevalence of HBsAg among those children who have been immunized (33). In spite 
of this lack of data regarding evaluation of the pilot project the Government of India 
decided to include the Hepatitis B vaccine in a phased manner throughout the country. 
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The Government of Tamil Nadu launched Hepatitis B as part of the universal 
immunization program in January 2008. 
 One reason for not including a birth dose was that perinatal transmission was not 
considered to be the major form of transmission. This was because the proportion of 
women who are HBeAg positive among those who are HBsAg positive, varies from 8 
to 47%, with most studies showing 18% or less (46). The other reason was the low rate 
of antenatal care and institutional deliveries. The proportion of antenatal mothers who 
had at least 3 antenatal care visits for their last birth was only 50.7% in India while it 
was 96.5% in Tamil Nadu (47). Also since institutional deliveries in India was only about 
40% and deliveries conducted by health personnel 48%, it has been argued that it was 
not feasible to give the birth dose to all children (48). 
 In Tamil Nadu however, the proportion of institutional deliveries was 90% and 
deliveries conducted by skilled personnel was 93% (47). However, only 64.2% of the 
deliveries occur in the government facilities, 39.7 % occurring at government hospitals, 
20.6% at primary health centers and 4.5% at health sub centers (49). Testing all pregnant 
women for HBsAg and giving selective immunization would be difficult in other parts 
of the country where there is a lack of adequate antenatal services as available in Tamil 
Nadu.  
One community based study conducted in Delhi showed the feasibility of this ‘screen 
and vaccinate’ strategy, giving Hepatitis B immunization at birth using community 
health workers, but the effectiveness of reducing transmission was not shown(34,50). 
There is a lack of community based studies showing the effectiveness of selective 
immunization. 
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3.9 Hepatitis B immunization coverage worldwide 
In 1991, the Global Advisory Group of the Expanded Program on Immunization 
recommended integration of the Hepatitis B vaccine into immunization programs by 
1995, in countries with a HBV carrier prevalence of 8% or higher. It also set 1997 as 
the target for all other countries to achieve this goal. In 1994 the World Health 
Assembly set the goal of achieving an 80% decrease in new Hepatitis B child carriers 
by 2001.  As of December 2007, 171 countries have incorporated Hepatitis B 
immunization in their national immunization schedules and 139 countries have vaccine 
coverage of at least 80 %(10) 
Most countries which have intermediate to highly endemic hepatitis B have now 
achieved 65-100% coverage with the vaccine. Some low endemic Northern European 
countries immunize only groups at higher risk while other low endemic countries have 
universal infant or adolescent programs.   
3.10 Vaccine efficacy and effectiveness  
Vaccine efficacy refers to the protective effect of the vaccine against a disease or 
infection under idealized conditions. Before a vaccine can be introduced in an 
immunization program other factors besides efficacy, e.g. costs, logistics, secondary 
effects, adverse effects, herd immunity also need to be considered (51). These 
characteristics taken together comprise what is referred to as vaccine effectiveness or 
the vaccine efficacy under program conditions. Effectiveness is best estimated in 
evaluative studies (like randomized control trials) in which the unit of intervention and 
analysis are populations and not individuals. Ideally effectiveness of the vaccine should 
be measured in terms of the protection it offers against disease. Most trials measure 
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surrogate outcomes i.e. HBsAg positivity and anti HBs due to the difficulty and long 
follow up period required, if one were to study clinical outcomes like chronic hepatitis, 
cirrhosis of the liver or hepatocellular carcinoma. 
In spite of active immunization and administration of Hepatitis B immunoglobulin 
within 24 hours of birth, 5-10% of the children suffer from immunoprophylaxis failure, 
i.e. they become carriers of HBsAg. The main risk factors which have been found to be 
significantly associated with failure of immunization were HBeAg seropositivity and 
HBV DNA seropositivity in the mothers (52).  
Another explanation for vaccine failures is the theory of ‘vaccine escape mutants’. 
Some infants may be infected with HBV variants which bear single point mutations in 
the HBV surface antigen. Due to this mutation binding of anti HBs to the antigen is 
blocked, which explains why the antigen is not cleared in spite of the presence of 
circulating anti HBs (53,54). Both immunization as well as treatment may be reasons for 
selection and amplification of these variants in anti HBs positive hosts. Some studies 
have shown that a part of these HBV mutant variants are maternally derived and that as 
good immunization practices with regard to Hepatitis B immunization increase, there 
are  higher chances of these variant forms emerging.  
The prevalence of vaccine escape mutants is low in most studies (54).  In India, a study 
from Chennai showed a prevalence of 2.9% of Hepatitis B virus variants among 68 
children followed up for 2 years, who were successfully vaccinated  at birth, 1 and 6 
months and (55). Although the problem of vaccine escape mutants has not yet evolved 
into a public health problem it is recommended to monitor the emergence of these 
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variants (56). Another factor contributing to failure of immunization is the presence of 
high levels of HBV DNA in the mother (57). 
3.11 Anti HBs concentration after immunization and factors associated with 
persistence 
A study comparing the antibody levels achieved by three different types of recombinant 
DNA vaccines showed GMT values of 226.7, 193.9 and 173.6 mIU/ ml one year after 
completion of three doses(58). A higher prevalence of antibodies has been found with 
DNA recombinant vaccines as compared with plasma derived vaccines and with four 
doses as compared with three doses of the vaccine (59). The immunization schedule, age 
at receiving first dose of vaccine, amount of HBsAg present in the vaccine, 
administration of Hepatitis B immunoglobulin, higher peak antibody response are all 
shown to be associated with persistence of anti HBs levels (60). Studies have also shown 
that increase in the duration between the first two doses does not significantly affect 
immunogenicity or effectiveness(61). Accelerated schedules like 0, 1, 2 months increase 
the proportion of those who complete the course of immunization, but require a fourth 
dose to reach antibody levels comparable to other schedules(45). 
Follow up studies years after immunization have shown that anti HBs levels 
progressively decline with age (62). It has been shown that the anti HBs concentration 
decreases 10 years after immunization, to less than 10 mIU/ml, in 10-50% of vaccinees. 
However although antibody levels decline to undetectable levels, it has been shown that 
adequate immune memory exists after the primary vaccine series as seen by an 
anamnestic response to a repeat exposure to the antigen many years later. This is 
because immunization induces B and T memory cells which proliferate rapidly 
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producing antibodies and cytokines during the repeat exposure to a booster leading to a 
more rapid, larger and qualitatively different response. This response is also effective 
when there is exposure to the disease agent even after antibody level declines to 
undetectable levels. This anamnestic response is seen in more than 95% vaccinees even 
after 10 years of primary immunization (63). Thus a booster dose is not considered to be 
necessary. 
Studies have shown that one dose of Hepatitis B immunoglobulin (HBIG) given at birth 
does not interfere with the active production of anti HBs and the combination produces 
immediate and sustained high levels of the antibody (7). However, since there is not 
much of an added benefit of Hepatitis B immunoglobulin in comparison to 
administration of the vaccine alone, the consensus at the meeting of the Viral Hepatitis 
Prevention Board was that national policies of administering vaccine alone were 
justifiable (25). 
Although there is no need to routinely test everyone who receives the Hepatitis B 
vaccine for antibody levels, the WHO specifies certain conditions where testing may be 
done. This includes infants born to HBsAg positive mothers and sexual partners of 
HBsAg positive persons. The time period at which testing is recommended is at 8-15 
months of age, after completion of the vaccine series which is expected to be latest 
around 6 months. (3) 
According to the ACIP, post immunization testing for anti-HBs and HBsAg should not 
be performed before age 9 months, to avoid detection of anti-HBs from HBIG 
administered during infancy and to maximize the likelihood of detecting late HBV 
infection. Anti HBc transferred trans-placentally may persist till 24 months of age (19). 
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3.12 Impact of Hepatitis B immunization programs 
The long term impact of integrating Hepatitis B immunization in national immunization 
schedules is best studied in those countries which have a long history of running such 
programs. One such example is Taiwan, where the effectiveness of the immunization 
after 20 years has been proved (32). The carrier rate of Hepatitis B in Taiwan was 15-
20% in the era prior to immunization. Some of the landmark studies by Beasley et al 
were done in Taiwan assessing the effectiveness of Hepatitis B immunization and the 
Hepatitis B immunoglobulin the association between HBsAg and hepatocellular 
carcinoma (26). Based on the findings of these studies a nationwide immunization 
program was launched in 1984. During the first two years of the program only infants 
born to HBsAg positive mothers were offered immunization. Immunization was 
gradually extended to all newborns, preschool children, elementary school children, 
health workers, and finally to teenagers and adults on a fee-for-service basis. 
To assess the effectiveness of the immunization program a study was done using 3,464 
randomly selected vaccinees tested at 18 months of age. Among the children born to 
HBeAg positive mothers the HBsAg positivity rates were 14% for those who received 
the vaccine and immunoglobulin on schedule, as compared to 20% among those who 
received only the vaccine on schedule. The overall protective effect was found to be 
85%. Among infants born to mothers who were HBeAg negative the rate of HBsAg 
positivity was 3% for those who received the vaccine on schedule and 7% for those 
who did not receive the vaccine on schedule (p < 0.003). Studies were conducted at 
different times and places in the post immunization era, which showed significant 
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decreases in the prevalence of HBsAg carrier state as well as infant mortality due to 
fulminant hepatitis and hepatocellular carcinoma (32).  
There were many reasons which contributed to the success of the program in Taiwan 
(32). These included a motivated government, an efficient public health care system, 
extensive research and involvement of the public. There was also a robust system of 
registration of patients with any type of cancer, reporting of deaths and a complete and 
accurate national immunization registry which provided the individualized data needed 
to evaluate the program. 
Based on the success of the Hepatitis B immunization program in Taiwan it was 
suggested that when available, individualized data among recipients of the 
immunization program should be analyzed as part of a post immunization surveillance 
program. This should incorporate data from cancer and death registries, immunization 
registries, immunization records etc. Such data would help in conducting effectiveness 
and cost-effectiveness studies on the Hepatitis B immunization program. 
3.13 Number Needed to Screen 
Number Needed to Screen (NNS) is defined as the number of people that need to be 
screened for a given duration to prevent one death or adverse event. This measure 
provides a chance to compare efficacies of screening strategies.  
 NNS =                    Number Needed to Treat for risk factors    
                                 Prevalence of unrecognized disease 
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Number Needed to Treat (NNT) is defined as the number of people that need to be 
treated for a given duration to prevent one death or one adverse event.   
NNT = 1/ Absolute Risk Reduction (ARR)  
 A positive value for NNS implies that screening prevents an adverse outcome and a 
negative number implies that screening increases the adverse outcome (64). 
3.14 Cost effectiveness of alternate programs for Hepatitis B immunization 
3.14.1 Universal Immunization 
Universal immunization beginning at birth would be the ideal method of reducing the 
prevalence of the HBsAg carrier state as it would be effective in preventing perinatal 
transmission as well as early childhood transmission. However difficulties in 
developing countries include a lack of institutional deliveries, unavailability of the 
vaccine in small health facilities and costs involved in universal immunization. As there 
are around 25 million surviving live births per year approximately 75 million doses of 
the vaccine are required. The government estimated that the cost of universal 
immunization would be Rs. 525 crores (65). 
3.14.2 Selective Immunization 
Selective immunization by screening antenatal women and immunizing the children 
born to Hepatitis B positive mothers is an alternative strategy to reduce perinatal 
transmission. In certain European countries like the UK with a prevalence of 0.14% 
among antenatal women, this strategy is followed for childhood Hepatitis B 
immunization (66). 
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In India there are conflicting data regarding cost effectiveness of universal versus 
selective immunization. In order to calculate cost effectiveness of selective versus 
universal immunization it is necessary to obtain data on magnitude of morbidity and 
mortality associated with the disease, which is lacking in India (41). Thus the estimates 
that are possible with the current data are mostly based on some form of mathematical 
modeling.  
A community based study conducted in Delhi by the St. Stephen’s Hospital, found the 
true prevalence of HBsAg positive antenatal women to be 1.47%. Antenatal screening 
for HBsAg was followed by selective immunization of the children born to HBsAg 
positive mothers starting at birth or within 48 hours. The cost of selective immunization 
was calculated as the costs of testing all women during the first pregnancy; costs of 
salary and travel for a health worker to administer the birth dose and the cost of three 
doses of the vaccine. Given that the cost of the vaccine was Rs. 70 and the HBsAg test 
Rs.30, the projected cost for the country to implement universal immunization 
commencing at birth was calculated to be Rs. 5000 million. Assuming the number of 
deaths due to HBV related carcinoma to be 5000, the cost per life saved was estimated 
to be Rs. 1,000,000. As the cost per Quality Adjusted Life Years saved was found to be 
Rs. 48,540 which was more than twice the value of India’s Gross National Product, it 
was stated that the cost-benefit ratio of universal immunization was high (34). One of the 
criticisms of this study was that the benefits of universal immunization were 
underestimated, as the number of deaths related to HBV would be higher if deaths from 
cirrhosis were included to those from hepatocellular carcinoma. Since this study did not 
measure the success of the program in delivering the birth dose or the effectiveness of 
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the selective immunization strategy, a cost benefit ratio could not be calculated for 
selective immunization (50). 
A cost minimization analysis done in Delhi calculated the cost of universal 
immunization starting at 6 weeks to be twice as much as the cost for selective 
immunization, assuming that the proportion of carriers due to vertical transmission was 
50%. Assuming that 66% carriers were due to horizontal transmission, it was estimated 
that universal immunization would be as cost-effective as selective immunization if the 
carrier rate was 1.1%(67). 
Other studies have shown that universal immunization was more cost effective 
compared to selective immunization strategies (8). A review of economic evaluations of 
different strategies revealed that universal immunization was cost effective in areas of 
low, intermediate and high endemicity but data from areas of low endemicity were 
controversial(68). One of the reasons for the cost effectiveness of universal immunization 
was that the cost of the Hepatitis B vaccine has fallen dramatically since the early 1980s 
to less than 1 USD per dose. Also the effectiveness of selective immunization strategies 
depended to a large extent on the capability of the program to screen a high proportion 
of the target group and successfully vaccinate those at risk. 
3.15 Importance of the birth dose and difficulties involved in administration 
Reduction in deaths due to Hepatitis B is much greater with administration of the birth 
dose than without it. A flexible mathematical model was developed by Goldstein et al 
which allowed predictions to be made on mortality and morbidity related to Hepatitis B, 
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as well as estimation of the reduction in mortality achieved by different immunization 
strategies.  
According to this model, universal immunization without the birth dose would prevent 
up to 75% of global Hepatitis B Virus (HBV) related deaths, depending on coverage for 
the complete series. As coverage for the third dose increases from 50% to 90%, the 
reduction in HBV related deaths is expected to increase from 38% to 68% respectively.  
Administration of a birth dose to 50% and 90% of the vaccinated cohort would increase 
the proportion of HBV related deaths prevented from 77% to 84%, when the coverage 
for the third dose of the vaccine is 90%. With 100%  immunization coverage and all of 
the immunized children receiving the birth dose, it would be theoretically possible to 
prevent 95% of HBV related deaths (69). 
Administration of the birth dose depends largely on the place and provider of maternity 
care, the coordination between the National Immunization Program and maternal health 
care services. Institutional deliveries occur in public or private health facilities with or 
without access to a continuous cold chain. Although it is more feasible to administer the 
birth dose in the case of institutional deliveries as compared to home deliveries, studies 
from developing countries have shown that the birth dose may be delayed or missed 
even when the delivery takes place in the hospital. This can occur due to lack of 
coordination between maternity staff and those involved in immunization, non 
availability of the vaccine 24 hours of the day or referral to a different centre for 
Hepatitis B immunization (37). This is especially true in the case of deliveries occurring 
at lower level health facilities where the cold chain may not be available. 
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The WHO has suggested a few common guidelines irrespective of place of birth, for 
improving the coverage of the birth dose (37). 
 1. The planning stage for incorporation of the birth dose in the Hepatitis B 
immunization schedule should include a situation analysis of perinatal health services. 
It must also involve the maternity staff, besides nurses or pediatricians who are usually 
involved in immunization services.  
2. There must be a high priority accorded to increasing the proportion of deliveries 
conducted by trained personnel. A health worker must be designated to provide the first 
dose at home for home deliveries after receiving information about the birth. The 
program must also progress gradually from ensuring 100% coverage among 
institutional deliveries to increasing coverage among home deliveries.  
3. The availability of the vaccine for maternity staff must be ensured at all times even if 
it means keeping the vaccine out of the cold chain for a short while. 
4. There should be adequate recording and reporting of the birth dose. This step may 
involve modification of the immunization card for entering the date and time of 
receiving the first dose of Hepatitis B vaccine. 
3.16 New methods of Vaccine delivery  
One of the difficulties in achieving universal immunization is the non availability of the 
vaccine when the delivery occurs either at home or at a health facility without access to 
the cold chain. As the Hepatitis B vaccine remains stable at room temperature even up 
to one month, the WHO allows for storing and using the vaccine even out of the cold 
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chain. This is subject to certain conditions being fulfilled, such as the vaccine having 
remained in the cold chain but never frozen, at all other points before reaching the 
lowest point of use and the presence of a vaccine vial monitor. 
The use of pre-filled syringes for immunization is another strategy which has been used 
to improve the coverage of Hepatitis B immunization. In India a study using Shanvac-b 
showed that a single use pre filled device Uniject when used in infants at 0, 1, 2 months 
gave 100% seroprotection and a GMT of 385.4 mIU/ml, 4-6 weeks after the third dose 
(70). These may be future options for the Indian government, to enable introduction of 
the birth dose in the Hepatitis B immunization schedule. 
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4.  METHODOLOGY 
4.1 Study Design  
The study was an evaluation of the program for prevention of vertical transmission of 
Hepatitis B. The program was an intervention study without a control group. The 
prevalence of Hepatitis B infection among the antenatal women and the effectiveness of 
the program in delivering the specified vaccine schedule, including the birth dose were 
estimated. A cross sectional serological survey of the children born to the women who 
tested positive for HBsAg was also carried out. Thus the overall effectiveness of the 
program in preventing vertical transmission of Hepatitis B under field settings was 
determined. 
4.2 Background of the study and description of the program 
The Community Medicine department of the Christian Medical College (CMC 
Hospital) is situated in Kaniyambadi a rural block in Vellore district. The department 
also called CHAD (Community Health and Development program), runs a secondary 
hospital and has been serving this area for the past 50 years. The block consists of 88 
villages and a population of 1, 04,832 with a crude birth rate of 13.9/1000 population. 
The referral centre for CHAD hospital is a multi-specialty tertiary hospital, the 
Christian Medical College, Vellore. Antenatal women with complications during 
pregnancy or delivery are referred to this hospital. 
The CHAD program provides primary health care to the people of Kaniyambadi in a 
form similar to the government services. At the village level is a part-time community 
health volunteer who is an elderly lady selected by the community and lives in the 
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village itself. The next level is a ‘health aide’, a trained health worker similar to the 
Village Health Nurse in the government services, who supervises 4-5 part time 
community health volunteers and covers a population of around 5000. A public health 
nurse supervises 3-4 health aides and a doctor is appointed for every 30,000 
population. The health team of the doctor, public health nurse, the health aide and the 
community health volunteer conduct a mobile clinic every month in each village.  
The services provided are antenatal care, Hepatitis B immunization, treatment of minor 
ailments and chronic diseases. A home based antenatal card is provided at the first 
visit. The women who receive antenatal care at the mobile clinics are categorized as 
‘permanent’ residents or ‘temporary’ residents, the latter being those women who 
previously belonged to families in the service area and who come back for the first 
delivery to their own mother’s house.   
 In May 2002 it was decided to screen antenatal women for HIV and Hepatitis B. This 
involved administration of a written consent form by the doctor at the first visit, 
followed by collection of 5 ml of blood. At the time of blood collection consent was 
also obtained for storing and using any residual sample for further studies in the future. 
The collected samples were transported back to the base hospital on the same day and 
the sera separated. The kit used for testing for Hepatitis B was a rapid one step 
immunoassay, Hepacard (sensitivity 99.8% and specificity >99% according to 
manufacturer), manufactured by J.Mitra and Co.Pvt.Ltd, New Delhi in collaboration 
with Program for Appropriate Technology in Health. Residual sera from all patients 
were stored in a deep freezer at -20 degrees C, irrespective of the result of the tests. 
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At the base hospital CHAD conducts a weekly antenatal and immunization clinic 
where women and children from Vellore and surrounding areas are registered. In 2004, 
antenatal screening for HIV and HBsAg was extended to all the women who came to 
CHAD hospital for antenatal care. At the first visit there was a group teaching on the 
importance of screening, modes of transmission and prevention of Hepatitis B and HIV 
following which consent was obtained for testing. 
Women who tested positive for HBsAg through either system of antenatal screening 
(peripheral or base hospital), received post test counseling by a senior doctor in the 
special clinic for high risk antenatal women at CHAD. During the post test counseling, 
Hepatitis B surface antigen positive mothers were advised hospital delivery and 
Hepatitis B immunization for the children commencing at birth. In case a woman 
delivered at home, the family was advised to bring the child for the first dose of the 
vaccine within 24 hours of birth. The need for Hepatitis B vaccine for the child was 
mentioned on the mother’s card but the fact of the mother being HBsAg positive was 
not highlighted for the sake of confidentiality. The schedule followed for 
immunization was a birth dose of Hepatitis B vaccine, followed by two more doses at 
1 and 2 months. The second and third doses were administered in the mobile clinics 
and all the three doses were provided free of cost to the children born to Hepatitis B 
positive mothers. There was no administration of a booster dose.   
 The data regarding vital events, antenatal care and immunization which were collected 
every week by the health aides with the help of the community health workers, were 
verified by the nurse and doctor. This information was entered in the computerized 
health information system, from which information is available on all pregnancies in 
the block since 1986. 
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4.3 Study Population 
The database of all the antenatal women who were registered with CHAD during the 
study period was obtained. This included both women from the service area, 
Kaniyambadi block, as well as those who were from other areas who registered at the 
base hospital CHAD. All children 6 months of age and above born to women who 
tested positive for HBsAg during the study period were eligible for the serological 
study.  
4.4 Sample Size 
Sample size was calculated as the sample size for difference between proportions 
 
p1 (proportion of children becoming chronic carriers without immunization) = 18.6 x 
90 % = 17 % and p2 (proportion of children becoming chronic carriers with 
immunization) = 25% x 17 = 4 %  
The assumptions made were a perinatal transmission rate of 18.6 % according to 
Nayak et al in 1987, 90 % rate of chronic infection among newborns infected with 
Hepatitis B and vaccine efficacy of 75% (5,26) 
 For the significance level α =0.05, the two tailed deviate Z= 1.96; and for power (1-β) 
= 0.80, Z = 0.842 
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 The sample size was 84 in each of two groups, one of which received and the other 
which did not receive the immunization and therefore the total number required was 
168 children born to Hepatitis B positive mothers. 
4.5 Collection of data 
4.5.1 Recruitment of study subjects: 
The names and addresses of women who had tested positive for HBsAg during the 
antenatal screening were obtained from the CHAD database. Children of mothers, who 
tested positive for Hepatitis B surface antigen, were eligible for this study if at least two 
months had elapsed since the last dose of vaccine. The age group of the eligible 
children was taken as above 6 months to ensure this. Female health workers from the 
service area were asked to refer the HBsAg positive women and their children for the 
study. Letters were sent to women who were from the non service areas informing them 
about the study. Home visits were made for those who did not respond to the mail, for 
patients residing either in Kaniyambadi block or in Vellore town. All the women and 
children were asked to come on a scheduled day of the week bringing their antenatal 
cards and the immunization cards. 
4.5.2 Obtaining consent 
Written consent in the local language was obtained (see Annexure 2) from the mother. 
In case the mother could not be interviewed due to unavoidable reasons, the father or 
other relative who brought the child gave consent. 
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4.5.3 Questionnaire 
The questionnaire was administered to the mother/guardian of the study child. The 
questionnaire covered details of delivery, immunization of the child, as well as 
acceptance and compliance to the program protocol (Annexure 1). The timing of the 
birth dose was confirmed from the in-patient records for those born in either CHAD or 
CMC hospital. Information on 2nd and 3rd doses was obtained from patient retained 
immunization cards or hospital records. 
4.5.4 Serological testing 
As part of the evaluation 5 ml samples of blood were obtained from the study child. The 
separated sera were sent to the Virology laboratory of the Christian Medical College for 
the tests. The test kits used were the DIASORIN HBsAg kit, AXSYM AUSAB, a micro 
particle enzyme immunoassay (MEIA) for the quantitative determination of anti HBs 
and AXSYM CORE (Abbott Laboratories) an MEIA for anti HBc. When the titre of the 
neat serum sample was above 1000 mIU/ml, the sera were tested after diluting the 
sample in human sera which was negative for anti-HBs and HBsAg. The stored sera of 
the mothers were retrieved and HBeAg testing was done in order to determine if higher 
infectivity interfered with the protective effect of the vaccine. HBV DNA testing could 
not be done as the samples were not cryo preserved and the cost involved would have 
been high. 
Study children were tested for HBsAg, to check for carrier status of the child; anti HBs 
to check for seroconversion after immunization and total anti HBc to look for other 
evidence of infection. Only children above 24 months were tested for anti HBc in order 
to avoid detection of maternally derived antibodies. 
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4.5.6 Non-respondents 
The information regarding delivery and immunization status of the children was 
obtained from hospital records for children from the service area who could not be 
contacted. Similar data on immunization was not available for those children born to 
women who had registered at the base hospital but could not be contacted for the 
present evaluation. 
4.6 Data entry and analysis 
The data was entered using EpiData version 3.1.The software used for analysis of the 
data was SPSS for Windows version 12. The primary outcome analyzed was 
occurrence of HBsAg among the children who were tested and subgroup analyses were 
done according to the type of immunization schedule followed and the mother’s 
HBeAg status. The other outcome measures for vaccine effectiveness were occurrence 
of anti HBc and presence of antiHBs of more than or equal to10 mIU/ml at the time of 
testing. Calculation of Geometric means Titres (GMTs) involved logarithmic 
transformation of the values of anti HBs. 
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5. RESULTS 
 
5.1 Antenatal screening for Hepatitis B surface antigen (HBsAg) 
Women from the service area Kaniyambadi block, registered for antenatal care with 
CHAD through the services offered at the village level. Since May 2002 routine 
screening for HIV and HBsAg infections was offered to all the antenatal women who 
were registered. From the month of May 2002 till December 2007 there were 12,977 
pregnancies in Kaniyambadi block. Of all the pregnancies in the block 12,038 women 
who registered for antenatal care with CHAD were offered antenatal screening for HIV 
and HBsAg. There was only one woman who refused consent for antenatal testing. The 
rate of screening for HBsAg was 93% among all the pregnancies in the block between 
May 2002 to December 2007 and 99.9% among those who registered with CHAD for 
antenatal care.  
Since April 2004, antenatal screening for HBsAg and HIV was started for all the 
antenatal women who attended CHAD hospital for antenatal care. Since the beginning 
of the program till December 2007, 9130 women registered for antenatal care and only 
one refused blood testing for HBsAg. Thus 9129 were screened during this period. 
5.2 Prevalence of Hepatitis B surface antigen 
5.2.1 Point prevalence of HBsAg infection among antenatal women in 
Kaniyambadi block: 
Analysis of the data from the CHAD service from 2002 showed that, of the 12,037 
pregnancies that had been tested, 190 had been detected to be HBsAg positive. Of all 
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the women who tested positive for HBsAg, 40 women had been tested again in a 
subsequent pregnancy during this period. Thus the number of women who were 
identified to be HBsAg positive was 150 out of 11997 women who had been tested. The 
prevalence of HBsAg positive women ranged from 1.31% to 1.78% as shown in Table 
No.2. The overall point prevalence of HBsAg infection was 1.25% (95% CI 1.05%-
1.45%) among antenatal women of Kaniyambadi block during this period. 
Table No. 2 Prevalence of HBsAg in Kaniyambadi block 
95%CI 
Year 
No. of 
pregnancies 
who were 
tested 
No. of test 
positives 
HBsAg 
Prevalence 
% Lower Upper 
2002 1513 27 1.78 1.12 2.45 
2003 2043 36 1.76 1.19 2.33 
2004 2204 29 1.32 0.84 1.79 
2005 1997 29 1.45 0.93 1.98 
2006 2077 29 1.40 0.89 1.90 
2007 2203 40 1.82 1.26 2.37 
Total 12037 190    
Chi-square for trend = 0.037, p = 0.847 
5.2.2 Point prevalence of HBsAg infection among antenatal women attending 
CHAD hospital: 
From April 2004, there were 9130 pregnancies registered at the base hospital, CHAD 
from places both in and around Vellore. All of them were offered antenatal screening 
for HIV and HBsAg and only one refused screening. Thus the number of positive 
samples among the 9129 pregnancies which were screened was 148. Of these 148 
pregnancies, 18 were women who had been tested again during subsequent pregnancies.  
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The yearly prevalence of HBsAg positivity ranged from 1.40% to 1.82% as shown in 
Table No. 3. The overall prevalence of HBsAg among women from non service areas 
attending CHAD hospital for antenatal care was 1.43 % (95% CI: 1.18%-1.67%) which 
was 130 out of 9111 women screened. 
Table No. 3 Prevalence of HBsAg among antenatal women attending CHAD 
hospital 
95%CI 
Year No. of pregnancies 
No. of test 
positives 
HBsAg 
Prevalence 
% Lower Upper 
2004 1562 26 1.66 1.03 2.30 
2005 2186 35 1.60 1.07 2.13 
2006 2629 37 1.40 0.96 1.86 
2007 2752 50 1.82 1.32 2.32 
Total 9129 148    
 Chi-square for trend = 0.12, p value = 0.729 
5.3 Description of pregnancies in Kaniyambadi block (May 2002-December 2007) 
During the study period there were 12,977 pregnancies in Kaniyambadi. The 
description of pregnancies and their outcomes were available in the CHAD database for 
12,016 women out of the 12,037 who underwent screening for HBsAg. The number of 
HBsAg positive women for whom complete information was available for analysis was 
183 out of the 190 women who were test positive. Of the remaining, two aborted; one 
woman committed suicide; two moved out and two who were temporary residents lost 
to follow up during the antenatal period, were later found to have delivered live 
children. Table No. 4 is a comparison of prevalence of HBsAg among women of 
different residence statuses and obstetric scores. It was found that there was no 
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significant difference between the prevalence of HBsAg by residence or obstetric scores 
(gravida, parity, number of living children and number of abortions). 
Table No 4   HBsAg prevalence by selected characteristics of antenatal women 
Residence Total 
HBsAg 
positive 
(No)  
HBsAg 
positive 
(%) 
p value (Chi-
square) 
Temporary 3711 64 1.72  0.228 
Permanent 8305 119 1.43  
Gravida     
1st 5250 80 1.52 0.995 
2nd or more 6766 103 1.52  
Parity     
1 4549 73 1.6 0.549 
2 or more 1788 25 1.4  
Living children     
0 5904 87 1.47 0.664 
1 or more 6112 96 1.57  
Abortions     
0 10766 164 1.52 0.993 
1 or more 1250 19 1.52  
 
Table No 5 describes the outcomes of 12,016 pregnancies among those who underwent 
antenatal screening for HBsAg from Kaniyambadi block , excluding abortions. 
Table No. 5  Outcomes of pregnancies in Kaniyambadi block 
 HBsAg positive N=178 
HBsAg negative 
N=11664 
Place of delivery No % No % 
CHAD 117 65.7 7305 62.6 
CMC 19 10.7 671 5.75 
Other Institutions 22 12.4 2587 22.2 
Home 20 11.2 1101 9.3 
Mode of delivery     
Vaginal delivery 166 93.3 10380 89 
Caesarian Section 12 6.7 1284 11 
Outcome of delivery     
Alive at day 7 172 96.6 11316 97 
Stillbirths 4 2.3 202 1.7 
Deleted:  
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There was no significant difference between the proportion of home deliveries between 
the groups of HBsAg positive and negative women (p = 0.379).There was also no 
significant difference between the proportions of vaginal and caesarian deliveries 
between the two groups (p = 0.07).  
The mean birth weight of the children born to the HBsAg infected women was 2.810 kg 
(SD 0.477) which was comparable to the mean birth weight of 2.805 kg (SD 0.479) 
among the children born to uninfected mothers. The perinatal mortality rate among the 
children born to HBsAg positive women was 34/1000 live births, compared to 31/1000 
live births among children of HBsAg negative women (p = 0.764 for perinatal deaths 
vs. healthy children). 
5.4 Children eligible for the prospective serological study  
The number of pregnancies which were HBsAg positive was 338 from May 2002 till 
December 2007 (190 from the service area and 148 from among the women who 
attended CHAD hospital). For the present evaluation children who were less than 6 
months old were excluded. Thus children who were born after 30th December 2007 
were not eligible at the time of testing. The number of children who were eligible for 
the current study was 269. Among the 269 children, 109 were from non service areas 
and 160 from the service area. 
Figure 1 shows the overall outcomes and eligible children of all the HBsAg positive 
pregnancies in Kaniyambadi block 
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Figure No: 1  Pregnancy outcomes and eligible children - Kaniyambadi block: 
 
Figure 2 shows the overall outcomes of all the HBsAg positive pregnancies registered 
at CHAD hospital. 
Figure No: 2 Pregnancy outcomes and eligible children - CHAD hospital: 
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 5.5 Types of immunization schedules followed (Kaniyambadi block) 
The immunization schedule as advised by the program was a dose of Hepatitis B 
vaccine at birth, followed by two further doses after one and two months.  
Immunization schedules followed by the children were available for 154 of the children 
born to HBsAg positive mothers from the service area. The data on immunization for 
those children who could not be contacted for the evaluation was obtained from 
immunization records. Table No 6 depicts the various schedules which were followed 
for immunization of the children born to the HBsAg positive mothers in the service 
area. The ‘birth dose’ in these schedules was given on the date of birth or the next day 
(within 48 hours). 
Table No: 6 Immunization schedules of children born to HBsAg positive mothers  
Type of vaccine schedule No. Percent 
Birth,1 month,2 months 81 52.6 
Birth,1 month,3 months 14 9.0 
Birth,1 month,4-6 months 7 4.5 
3 doses, including dose at birth 17 11.0 
3 doses, no birth dose 27 17.53 
Birth dose, Incomplete 
immunization 
0 0 
No dose at birth, incomplete 
immunization 
6 3.9 
No dose received 2 1.3 
Total 154 100 
     
 
 
Overall, the coverage for the birth dose was 77.2% among the 154 children in the 
service area for whom data was available. The proportion of children who received the 
vaccine according to the schedule advised by CHAD was 52.6%. Among the 154 
children 102 (66%) received any one of the standard schedules.   
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5.6 Descriptive statistics of the study population 
Of all the eligible 269 children, (160 children from the service area and 109 children 
from the CHAD hospital group), 131 children were available for the present evaluation. 
Thus the population evaluated constituted 112 women and 131 children, some of the 
women having had more than one child. 
Of the 131 children who came for the present evaluation, 98 (75%) were from the 
service area. Among the 160 children from Kaniyambadi block eligible for this study, 
70 of the 104 permanent residents (67%) and 30 of the 56 temporary residents (53.5%) 
participated in the evaluation. The family of one child refused to give consent and six 
permanent residents who had migrated out of the block could not be contacted. The 
proportion of eligible children who could be contacted from among the population 
served by CHAD hospital was 30% (33/109 eligible children).  
The age group of the 131 children who were tested ranged from 6 to 66 months (median 
28 months). First born children constituted 44.3 % (58/131) of the children who were 
screened. Of the 131 children tested, 92.4% were born in hospitals (80% were born in 
CHAD).  
Table No.7 shows the place of birth for children born to mothers registered either at the 
peripheral services in Kaniyambadi or at the CHAD hospital. Of the women who were 
available for the evaluation, 77% from Kaniyambadi block and 85% of women who 
registered at CHAD hospital from non-service areas delivered in CHAD. 
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Table No 7 Place of delivery 
 
 Place of delivery CHAD CMC HOME
Other 
HOSPITALS Total  
76 8 9 5 99 Kaniyambadi group 
  
CHAD hospital group 29 2 1 1 34 
Total 105 10 10 6 131 
  
 
5.7 Immunization coverage among study children  
5.7.1 Hepatitis B immunization schedules followed by the study children 
The exact dates of receiving the 3 vaccine doses were checked using immunization card 
or hospital records for 129 children. Two mothers had lost the immunization cards and 
hence parental recall of immunization doses was used. Table No.8 shows the 
immunization schedules followed by the 131 children who were available for the 
evaluation.  
Table No. 8 Immunization schedules followed by the study children 
Type of vaccine schedule Number percent 
Birth,1 month,2 months 72 55.0 
Birth,1 month,3 months 17 12.9. 
Birth,1 month,4-6 months 3 2.3 
3 doses, including dose at birth 16 12.2 
3 doses, no birth dose 15* 11.4 
Birth dose, Incomplete immunization 7 5.3 
No dose at birth, incomplete 
immunization 
1 0.8 
Total 131 100 
 
*3 of these children received Hepatitis B immunoglobulin at birth  
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The birth dose of the vaccine was received by 115 (87.8 %) of the study children. The 
number of children who followed the schedule as advised by the CHAD program (birth, 
1 and 2 months) was 72 out of the 131 children (55%). Overall 92 children (70%) were 
immunized according to any one of the accepted schedules i.e. birth, 1 and 2 months; 
birth, 1 and 3 months or birth, 1, 4 to 6 months. Among the study children 123 (93.9%) 
received 3 or more doses of the vaccine. There were 5 children who received only a 
single dose, which was given at birth.  
Of the 16 children who did not receive the birth dose, 4 were born at home; 3 were born 
in health centres out of the service area where the vaccine was not available; 3 received 
Hepatitis B immunoglobulin at birth followed by the vaccine later and 6 were born in 
CHAD but were not given the first dose of the vaccine on time. 
 The study population included 98 children from the service area. Of the remaining 62 
eligible children who did not come for the study, information regarding Hepatitis B 
immunization status was available for 54 children. The proportion of children who 
came for the study among those who received a birth dose of the vaccine was 72.3 % 
(86 out of 119). Of the 81 children who followed the schedule advised by CHAD, 56 
(69%) were available for the evaluation. Data on immunization status was not available 
for 6 children who were temporary residents and 2 children who were permanent 
residents who had moved out of the area. 
5.7.2 Time of receiving first dose of vaccine 
The information regarding exact time of receiving first dose of vaccine was available 
from hospital records for 89 of the 131 children. Median time of receiving the first dose 
was 65 minutes for these 89 children. The program was able to deliver the first dose of 
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the vaccine within 24 hours to 111 children (85%) and within 48 hours of birth to 115 
children (87.8%). 
5.8 Results of serological survey of the study children 
5.8.1 HBsAg positivity among the tested children 
Of the 131 children who were contacted for the evaluation, 8 were test positive for 
HBsAg giving an overall prevalence of 6.1% (95% CI: 1.92%-10.28%). Among the 115 
children who received the first dose of vaccine within forty eight hours, HBsAg was 
detected in 7 children (prevalence: 6 %, 95% CI: 1.57%-10.43%). HBsAg was positive 
in 5 of the 92 children who received three doses of the vaccine according to standard 
schedules (prevalence: 5.4%, 95% CI: 0.69%-10.1%). 
 
5.8.2 Results of anti HBc tests  
Anti HBc was tested only among the 74 children in the study who had completed two 
years of age and 6 were positive for anti HBc (8.1%). However only 59 of these 74 
children had received three doses of the vaccine including the birth dose and 5 of these 
(8.47%) were positive for either anti HBc or HBsAg. 
Table No.9 shows the immunized children who tested positive for either or both the two 
markers of infection namely, HBsAg and anti HBc. 
Table No. 9 Markers of infection among immunized children aged above two years  
 
Anti HBc Total 
HBsAg positive negative  
Positive 2 2 4 
Negative 1 54 55 
Total 3 56 59 
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5.8.3 Immunization schedule vs. HBsAg status of the study children  
In the present evaluation, 7 out of 115 (6.0%) children who received the first dose of the 
vaccine within 48 hours of birth tested positive for HBsAg compared to 1 out of 16 
children (6.25%) who did not receive a birth dose (Table No. 10). This difference was 
not found to be statistically significant (S.E. for difference between the proportions = 
7.55, p value = 0.976). The difference in rates of children with positive HBsAg tests 
was not significantly different even when the definition for birth dose was taken as 
having received it within 24 hours (p value=0.88).  
   Table No 10: Immunization schedule and HBsAg status of study children 
 
Type of  schedule No. of 
HBsAg 
positive 
children 
Percentage 
of HBsAg 
positive 
children 
Total no of 
children 
Birth,1 month,2 months 2 2.7 72 
Birth,1 month,3 months 3 1.8 17 
Birth,1 month,4-6 months 0 0 3 
3 doses, including dose at birth 1 6.3 16 
3 doses, no birth dose 1 6.6 15 
Birth dose, Incomplete immunization 1 1.4 7 
No dose at birth, incomplete 
immunization 
0 0 1 
Total 8  131 
  
Of all the 92 children who had received any of the accepted schedules, 5 children 
(5.4%) tested positive for HBsAg. Among those children who received non-standard or 
incomplete immunization schedules the rate of HBsAg positivity was 3 out of 39 
children (7.69%). This difference was not statistically significant (S.E. for difference 
between the proportions = 5.55, p = 0.681). 
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Out of the 8 HBsAg positive children, 7 had received the first dose of vaccine within 24 
hours but one finally received only two doses of the vaccine. Of all the 8 HBsAg 
positive children 7 had received three doses of the vaccine (Table No 10). 
5.8.5 Type of delivery and HBsAg status  
  
The proportion of children born by vaginal delivery was 91.6%. Among the 120 
children in the study group who were born by vaginal delivery, 8 children were found to 
be HBsAg positive. None of the 11 children born by LSCS were HBsAg positive. 
5.8.6 Anti HBs titres 
 
The Geometric Mean Titre (GMT) for children between 6-12 months who received 
three doses of the vaccine was 345.9 mIU/ml (95% CI: 91.8-568.9 mIU/ml).  
Among the 123 children who received three doses of the vaccine the seroconversion 
rate was 91% (children with detectable antibody levels). Anti HBs level of at least 
10mIU/ml is considered to be evidence of adequate seroprotection. Among the children 
between 6-24 months who received 3 or more doses of the vaccine, the seroprotection 
rate was 92.4% (49 out of 53 children). Of all the 123 children who received 3 or more 
doses of the vaccine, 93 (75.7%) were found to have antiHBs levels of greater than or 
equal to 10mIU/ml at the time of testing. 
 Table No.11 shows the proportion of children in each age group who had protective 
antibody levels at the time of testing. 
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                 Table No. 11 Age in months vs. Anti HBs levels 
Children with antiHBs >=10 mIU/ml  Age of children 
in months No. Sero protection (%) Total 
<=12 17 89 19 
13-24 32 94 34 
25-36 19 68 28 
37-48 10 63 16 
49-60 8 53 15 
61-72 7 64 11 
Total 93 75.7 123 
 
Of the remaining 30 children who did not have protective anti HBs levels at the time of 
testing 26 children (87%) were above two years of age. 
5.8.7 Effect of Hepatitis B Immunoglobulin on titres of anti HBs  
There were six children who were born in CMC who received Hepatitis B 
Immunoglobulin (HBIG) at birth. The average GMT of the 6 children who received 
HBIG (42.26 mIU/ml, 95% CI: 13.38-133.56) was not significantly different from that 
of children who did not receive HBIG (77.23 mIU/ml, 95% CI: 50.42-118.30). 
5.8.8 Anti HBs concentration and HBsAg positivity of the tested children 
There were 3 children who tested positive for HBsAg despite having antiHBs values of 
more than 10 mIU/ml at the time of testing. Table No 12 represents the HBsAg status of 
the study children and their anti HBs antibody levels. 
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Table No. 12  AntiHBs level vs. HBsAg status of the study children 
Anti HBs HBsAg positive 
mIU/ml No. % 
Total 
<10 5 13.5 37 
10-100 2 4.5 44 
101-500 1 2.6 38 
501-999 0 0 6 
>=1000 0 0 6 
Total 8 6.1 131 
 
 
5.8.9 Relationship between Anti HBs values and type of immunization schedule  
Table 13 shows the Geometric Mean Titres of anti HBs values for the children who 
received three doses of vaccine according to different vaccine schedules. The GMT was 
calculated for the 112 children who seroconverted out of 123 children who received 
three doses of the vaccine. The numbers of children who had taken different vaccine 
schedules in different age groups was small and some of the age groups had only one 
child who received a particular vaccine schedule. 
Table 13 shows that children who received the immunization at birth, 1 month and 3-6 
months of age had apparently higher antibody levels as compared to those who received 
the vaccine at birth,1 and 2 months except in the age group 6-12 months. In this age 
group (6-12 months) GMT of children who received the birth dose, 1 and 2 months 
schedule was 208 mIU/ml (95% CI: 65-668 mIU/ml) compared to 161 mIu/ml (95% 
CI: 56-458 mIU/ml) among those who received a birth dose followed by two doses at 1 
month and 3-6 months. 
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Table No 13 : Mean Anti HBs values by age group and immunization schedule 
Age in months and Geometric Mean titre(mIU/ml) 
Vaccine 
schedule 
<=12 13-24 25-36 37-48 49-60 61-72 
 GMT no GMT no GMT no GMT no GMT no GMT no 
birth,1,2 
months 
208 13 112 17 26 12 21 9 52 9 33 5 
birth,1, 
3-6 
months 
161 4 180 5 33 2 30 4 8 4 203 1 
3 doses, 
birth 
dose 
given 
 0 53 8 52 5  0   86 1 
3 doses, 
no birth 
dose 
3090 1 161 3 174 5 8 2 1 1 72 1 
Total 346 18 104 33 45 24 20 15 23 14 51 8 
 
However, on analyzing using ANOVA for the log transformed values of anti HBs, there 
were no significant differences between the anti HBs values achieved by different 
vaccine schedules in each age group. Antibody levels decreased with increasing age of 
testing as expected. 
Figure 3 is a line diagram which shows the mean anti HBs values in mIU/ml of 
different age groups according to the type of vaccine schedules. Some of the age groups 
in which there was only child who received a particular schedule were not represented 
on the graph. 
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Figure No 3: Comparison of mean anti HBs for different vaccine schedules 
 
 
 
 
5.9 HBeAg status of the mothers  
There were 129 stored samples collected during the antenatal period, from mothers 
whose children were available for the study with the rate of HBeAg positivity being 
16.3% (95% CI: 9.8% - 22.8%). 
 
5.9.1 HBeAg status of mothers vs. HBsAg status of children 
Of 115 children who received the birth dose of the vaccine HBeAg status was available 
for 113 of the mothers (Table No.14). The prevalence of HBsAg was more  among 
those children whose mothers were HBeAg positive compared to those whose mothers 
were HBeAg negative (RR = 2.1 ,95% CI: 1.05-9.09).  
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Table No. 14 HBsAg prevalence among children vs. HBeAg status of the mothers 
HBsAg status of 
children Total HBeAg status 
of mothers positive negative  
positive 2 16 18 
negative 5 90 95 
Total 7 106 113 
 
The transmission of infection overall from mothers who were HBeAg positive, to their 
children was 12.5 % (2/16) among children who received three doses of the vaccine 
starting at birth and 4.5 % (4/88) from HBeAg negative mothers (p=0.20). The relative 
risk was 2.77 (95% CI: 1.24- 9.63) for acquiring HBsAg if the mother was HBeAg 
positive. 
 
5.9.2 HBeAg status of mothers vs. markers of infection among the children 
 
There were 73 children greater than two years of age for whom anti HBc was tested and 
maternal HBeAg status was also done as part of the study. Of these children 59 were 
immunized with three doses of the vaccine including the birth dose. Table No. 15 shows 
the perinatal transmission of hepatitis B virus infection among these children with 
respect to maternal HBeAg status. 
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Table No 15:  HBeAg status of mothers vs. Hepatitis B infection among the 
children. 
  
HBsAg status of 
children 
HBeAg 
status of 
mothers 
Anti HBc 
status of 
children positive negative
Total 
positive positive 2 0 2 
  negative 0 4 4 
negative positive 0 1 1 
  negative 2 50 52 
  Total 4 55 59 
 
Of the 6 immunized children born to mothers who were HBeAg positive, 2 (33.3%) 
children showed signs of infection. Among the 53 children born to mothers who were 
HBeAg negative, 3 children (5.7%) showed evidence of infection (RR 5.8, 95% CI: 
1.58-21.11).  
5.10. Vaccine efficacy 
Assuming 18.6% as the rate of vertical transmission and 90% as the rate of chronicity 
of infection, the rate of chronic HBsAg infection among the unvaccinated children = 
17% (17). The prevalence of HBsAg among vaccinated children (present study) was 
5.4% (5 out of 92 children who received the birth dose of the vaccine and standard 
immunization schedules) 
Vaccine efficacy = HBsAg rate among unvaccinated- HBsAg rate among vaccinated 
                                             HBsAg rate among unvaccinated 
 
Vaccine efficacy = (17-5.4 /17) x 100 = 68 % 
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                                                6.  DISCUSSION 
 
 
6.1 Screening of antenatal women for HBsAg infection 
 
There are many studies from India on prevalence of HBsAg but very few are 
community based. These studies are based on different types of subjects like voluntary 
or replacement blood donors, children, antenatal women, special clinic attendees etc. Of 
all these groups the prevalence among antenatal women which is easier to obtain is 
often taken as being representative of the general population. However, even 
community based studies of HBsAg prevalence among antenatal women are not always 
representative of the prevalence in the general population, as often only a few women 
who receive antenatal care at a particular clinic are included. A few of these community 
based studies were actually based on high risk communities (14,15). 
The prevalence of HBsAg infection in the present study has been obtained by screening 
93% of all the pregnancies in one rural block (service area) between May 2002-
December 2007. This high rate of coverage was possible by actively identifying and 
registering antenatal women through services provided at the village level and was 
facilitated by the long standing relationship between the CHAD program with the 
people of the service area, Kaniyambadi.  
Of the remaining 7% of the women who could not be screened through this program, a 
few had antenatal care from other service providers, e.g. the government services, CMC 
hospital and private practitioners while others had gone with their husbands to different 
places to work during the antenatal period.  
A similar program of screening women for HBsAg would be successful only in places 
where the rate of women registering for antenatal care is high. According to the 
National Family Health Survey 3, the proportion of women who had three antenatal 
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care visits was only 50.7% in India while it was 96.5% in Tamil Nadu(47).Thus 
screening for HBsAg may not be feasible in states where the antenatal care is not as 
widely available or utilized. 
 Even among the antenatal women who came to the base hospital the acceptability for 
antenatal screening for HBsAg was high (99.9%), only one woman having refused the 
screening tests. 
 
6.2 Prevalence of HBsAg infection among antenatal women 
The point prevalence of HBsAg infection was 1.25% (95% CI: 1.05%-1.45%) among 
the antenatal women screened from the service area and 1.43% (95% CI: 1.18%-1.67%) 
among the antenatal women screened at CHAD.  
Although ideally the HBsAg test must be positive on two occasions 6 months apart 
before labeling a person as being a HBsAg carrier, this is not feasible in pregnancy. By 
the time the second test is done the patient may deliver and the chance to prevent 
perinatal transmission may be lost as not all women register in the first trimester of 
pregnancy. It is possible that if the women had been screened a second time 6 months 
later the prevalence of antenatal women who were HBsAg  positive would have been 
around 80% of  the present estimate(71). However, even if the vaccine were to be given 
to a few children who were actually not at risk for perinatal transmission, they would 
still be protected from horizontal transmission later on in life. Therefore in the CHAD 
program women were tested only once and as early as possible in their pregnancy, so 
that even if they did not come to CHAD for the delivery they would be aware of the 
need for Hepatitis B immunization for their children at birth.   
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The data obtained on prevalence from this study is that of point prevalence of HBsAg 
positivity and not of the HBsAg carrier state. This result was significantly lower than 
the estimated true prevalence of HBsAg positivity in India of 2.4% (95% CI: 2.2%-
2.7%) according to the meta-analyses done by Batham et al. This meta-analysis had 
shown that the chronic carrier rate in India was 1.9%, assuming that follow up testing 
after 6 months reveals 80% of persons who are HBsAg positive at initial testing to be 
chronic carriers (18). However, the data present from Kaniyambadi block was a 
community based study of a high proportion (93%) of antenatal women from a defined 
area, whereas the populations included in the meta-analyses included groups like 
voluntary and replacement blood donors. 
6.2.1 Trend of prevalence of HBsAg  
There was no significant trend of declining prevalence of Hepatitis B among the 
antenatal populations of both the service area (chi-square for trend= 0.037, p = 0.847), 
and the population served by the base hospital (chi-square for trend = 0.12, p value = 
0.729). However, the prevalence of HIV among antenatal women in the service area 
was found to have decreased from 0.59% in 2002 to 0.24% in 2006 (unpublished data). 
This was similar to data for Tamil Nadu where HIV prevalence decreased from 0.82% 
in 2003 to 0.58% in 2006. (72)  
It has been estimated that perinatal transmission contributes to 35-50% of chronic 
carriers in high endemicity countries and around 33% in India with the remaining 67% 
of chronic carriers in India acquiring the infection horizontally in childhood or 
sexually(5,20) . The exact contribution of each method of transmission is not known 
(17).The absence of a declining trend for HBsAg infection in an area where the HIV 
59 
 
prevalence has been found to be decreasing possibly due to concerted efforts in 
decreasing the sexual transmission of HIV, may be partly because a large proportion of 
HBsAg positive antenatal women may have been infected through either vertical 
transmission or horizontal transmission in early childhood. Therefore unless measures 
are taken to control perinatal transmission by ensuring Hepatitis B immunization at 
birth, it will be a long time before any significant decline in prevalence can be expected.   
 Various studies from Taiwan conducted at different intervals after the start of the 
immunization program, have shown the impact of universal immunization commencing 
at birth with the effect of reduction in HBsAg prevalence seen as early as 5 years later. 
A follow up study from Taipei showed a decrease in the prevalence of HBsAg among 
children under 5 years of age from 9.3% in 1984 to 2% in 1989(32) 
6.3 HBeAg positivity rates 
During the present evaluation HBeAg was tested among the women who were HBsAg 
positive and whose children were available for the serological evaluation. The rate of 
HBeAg positivity among the 129 women available for the study was 16.28% (95% CI: 
9.8% - 22.8%) which was similar to other Indian studies where the range was between 
7.8% - 47.8 % with most studies showing around 18% prevalence(17). This was 
considerably lower than the prevalence of HBeAg in East Asian countries like Taiwan 
(73). 
6.4 Strategies for prevention of HBsAg carrier state 
 
There are different strategies which are being followed worldwide for the prevention of 
transmission of Hepatitis B infection. These are universal immunization, selective 
immunization of high risk groups and a combination of both strategies. 
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6.4.1 Universal immunization 
 
Ideally universal immunization starting at birth would be the best way to prevent both 
vertical transmission as well horizontal transmission of Hepatitis B in early childhood. 
For preventing vertical transmission it is recommended to administer the first dose as 
soon as possible, preferably within 24 hours (19). This method of universal immunization 
commencing at birth has been shown to be the most cost effective method for 
preventing Hepatitis B carrier state (8,68). 
In India the recommended immunization schedule is three doses of Hepatitis B vaccine 
at 6, 10 and 14 weeks (9). Universal immunization without the provision of the birth 
dose does not help in reducing vertical transmission. This schedule was adopted 
because it was considered to be difficult to provide the birth dose to all newborns in the 
country. The other reason was that since the prevalence of HBeAg ranges from 8-47% 
with most studies showing estimates less than 18%, perinatal transmission was not 
considered to be a major contributing factor in transmission of HBsAg infection(46). 
 
6.4.1.1 Problems and Issues involved in universal immunization 
The WHO (Western Pacific Region) field guidelines for the administration of the birth 
dose of the Hepatitis B vaccine, has identified key issues involved in this process and 
suggested methods to ensure administration of the birth dose(37). One of the main 
problems was a lack of institutional deliveries or deliveries in low level health facilities 
where cold chain facilities are unavailable. 
However administration of the first dose of the Hepatitis B vaccine at birth is not 
unconceivable although it does require coordination between the maternity staff 
involved in the birth process and those involved in immunization. The practice of 
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administering injections to newborns is not a novel idea as most newborns receive 
Injection Vitamin K at birth and BCG vaccine is also given before discharging the 
mother from the place of delivery. For successful and timely administration of the birth 
dose of the Hepatitis vaccine either the maternity staff can be trained to give the vaccine 
or the staff in charge of immunization should be able to coordinate administration of the 
birth dose. 
Thus although it is theoretically possible to universally immunize all children at birth 
with the Hepatitis B vaccine, the difficulties include lack of the cold chain  at lower 
level health facilities like primary health centers, where a large proportion of deliveries 
occur and home deliveries. The other difficulty is the cost of universal immunization, 
which would be hard to justify given the increasing evidence that the prevalence of 
HBsAg infection is less than 2% making India a low endemicity region(18). The 
government of India has estimated the cost of universal immunization to be Rs. 525 
crores (65).   
 
6.4.2 Selective Immunization 
An alternative strategy to prevent perinatal transmission is screening antenatal women 
for HBsAg infection and ensuring immunization for their children commencing at birth. 
This strategy was employed by the CHAD program. This strategy of selective 
immunization is expected to prevent most of the perinatal transmission provided the 
coverage for antenatal screening is high. This strategy also relies on a high rate of 
institutional deliveries similar to universal immunization starting at birth. However in 
this case as the women who are HBsAg positive are few it would be easier to counsel 
them and ensure a high rate of institutional deliveries among these women. In countries 
like the United Kingdom where the prevalence of Hepatitis B among antenatal women 
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is only 0.14% this has been followed as the only strategy for childhood Hepatitis B 
immunization (66).  
The success of the CHAD program depended partly on ensuring institutional deliveries 
for women who were HBsAg positive. Therefore these women were advised 
specifically to deliver at CHAD or at any hospital where the vaccine could be given 
within 24 hours of birth. 
The proportion of all the antenatal women who had institutional deliveries during May 
2002-December 2007 was 93% in the service area (Kaniyambadi block). This was 
similar to the figure for Tamil Nadu (90%) and much higher as compared to 40.7% 
institutional deliveries for the country(47). The proportion of deliveries conducted by 
skilled personnel was 98 % in the service are as compared to 93% for Tamil Nadu. 
There was also no significant difference between the proportions of Hepatitis B positive 
and negative women who delivered in hospitals. In Tamil Nadu there has been a 
substantial increase in deliveries occurring at Primary Health Centers and childhood 
immunization is also being given in the PHCs rather than in health sub centers as was 
the practice earlier. Hence if this strategy under the National Rural Health Mission 
continues to work well in Tamil Nadu, it should be possible to give a dose of Hepatitis 
B vaccine at birth, especially if all carrier mothers were to be identified earlier. 
 
6.5 Compliance to the immunization schedule 
The children born to the HBsAg positive women were advised Hepatitis B 
immunization at birth, 1 and 2 months. The Indian Academy of Pediatrics recommends 
the first dose at birth, followed by two further doses one and three months later(48). The 
Advisory Committee on Immunization Practices (ACIP), CDC recommends a dose at 
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birth, second dose at 1-month and the third at 6 months (19). The recommendation is to 
give the first dose within 24 hours of birth, preferably within 12 hours of birth. 
The effectiveness of the program was 77% (102/154) in providing the birth dose to 
children of HBsAg positive mothers in the service area and 66 % in providing three 
doses as per standard schedules. Overall 94.8% of the children received three doses of 
the vaccine.  
Only the antenatal women who tested HBsAg positive and their husbands were 
informed about the need for immunization for their children during the post test 
counseling. In order to maintain confidentiality health aides of the service area were not 
informed about the results of antenatal screening and home visits were not made to 
follow up the children. 
6.6 Serological evaluation 
Of all the eligible 269 children born to HBsAg positive mothers from the service area as 
well as those who attended CHAD hospital for antenatal care, 131 were available for 
the evaluation and serological testing.  
 From the service area 67% of the children of permanent residents and 53% of the 
children of temporary residents were available. This is because the temporarily resident 
mothers were women who grew up in the service area, married and were now living 
elsewhere. They had registered with the CHAD peripheral services in order to have 
antenatal care and delivery at their maternal homes, as is the practice in this part of the 
country. Although attempts were made to inform all these women through their 
relatives residing in the service area, only a few of them were able to come for the 
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study. It was possible to contact only 30% of the children born to women who had 
antenatal care at CHAD hospital from non-service areas, since they resided over a wide 
area both within and outside the district.  
The sample size calculated was 168, of which 84 were expected to be in each group of 
those who accepted the immunization program and those who did not. Since there were 
only 8 children in the study group who did not receive the complete vaccine series and 
none who were completely unvaccinated, the rate of HBsAg infection among the 
unvaccinated children was taken from other studies for calculating vaccine efficacy. 
6.6.1 Coverage for the birth dose among the study children 
Among these 131 children available for the serological survey, the proportion who 
received the birth dose of vaccine was significantly less among those born at home 
(60%, 109 out of 121 children) compared to those children born in hospitals (90% 
coverage for birth dose, 6 out of 10 children), p value for chi-square=0.02. Studies have 
shown that even in hospitals there is a chance of not receiving the birth dose (37). The 
reasons for this problem in the present study included children being sick after birth; 
being born in health centers where the vaccine was unavailable or the health care 
providers were unaware of the HBsAg status of the mother. As the availability of the 
vaccine in public health facilities has increased it is less likely that in future the birth 
dose will be missed, due to non availability of the vaccine. 
6.6.2 Prevalence of HBsAg among the tested children  
Among the 92 children who received the three doses of the vaccine commencing at 
birth, the prevalence of HBsAg (failure of immunization) was 5.4%. Overall there were 
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8 children who were found to be HBsAg positive among the 131 tested children (6.1%). 
These children who were found to be HBsAg positive could have got the infection 
either perinatally from their mothers or through horizontal transmission later on in life. 
In either case this was an indication of failure of immunization. In order to determine 
the vertical transmission alone it would have been necessary to measure prevalence of 
IgM anti HBc in cord blood, which was not done as part of the present study. 
Transmission of infection to unvaccinated children could not be defined from our study 
as there was no child among the 131 tested children who was totally unvaccinated. 
The presence of HBeAg which is a sign of higher infectivity, has been shown to be a 
significant risk factor in perinatal transmission (24,73). In the present study children born 
to women who were HBeAg positive were twice as much at risk of acquiring HBsAg 
infection in spite of receiving a birth dose, as compared to those whose mothers were 
HBeAg negative (RR = 2.1 , 95% CI: 1.05-9.09). Thus HBeAg positivity of the mother 
was one of the significant factors associated with immunization failure. 
Presence of anti HBc which is also a sign of natural infection was tested only among the 
children who were above 2 years of age to avoid detection of maternally derived 
antibodies (19). There were 59 children above 2 years of age who received three doses of 
Hepatitis B vaccine including the birth dose, for whom maternal HBeAg was tested. 
The risk of the child becoming either HBsAg or anti HBc positive was significantly 
higher for children born to HBeAg positive mothers (RR 5.8, 95% CI: 1.58-21.11).  
Ideally women who are HBsAg positive should undergo testing for HBeAg and if 
positive their children must receive Hepatitis B immunoglobulin (HBIG) at birth (40). 
However HBeAg testing is not feasible in smaller level health facilities and the high 
cost of HBIG makes it impractical for use in developing countries. Besides, a review by 
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André and Zuckerman showed a protective efficacy of vaccine alone to be 90-100%, 
which was a difference of only 2-5% from efficacy of immunization as well 
administration of HBIG (92-100% efficacy)(6). Based on these factors, national policies 
of administering vaccine alone were considered to be justifiable at the meeting held by 
the Viral Hepatitis Prevention Board (25). Considering the above reasons the CHAD 
program did not do HBeAg testing for HBsAg positive mothers or administer Hepatitis 
B immunoglobulin to the newborns. 
6.6.3 Presence of both anti HBs and HBsAg  
The presence of anti HBs implies immunity which is acquired through natural infection, 
immunization or passive administration of Hepatitis B immunoglobulin. Immunity 
acquired through natural infection is evidenced by the presence of anti HBs as well as 
anti HBc whereas immunity acquired through immunization is indicated by the 
presence of anti HBs alone (19). It has been seen that occasionally there occurs the 
emergence of mutant forms of hepatitis B virus which can replicate in the presence of 
circulating anti HBs(53). It has been suggested that with increase in the immunization 
coverage there may be an increase in the development of these mutant form and 
therefore it is recommended to monitor the emergence of these forms (56). 
There were 3 children who were HBsAg positive despite having adequate antiHBs. The 
ages of these children were 5 months, 17 months and 45 months and all of them had 
received three doses of the vaccine staring at birth,1 and 3 months. HBsAg positivity in 
the presence of adequate anti HBs in these children implies infection by mutant forms 
of the virus which are not cleared by the circulating anti HBs.  
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The prevalence of children with both HBsAg and anti HBs was 3.3% in this study as 
compared to a prevalence of 2.9% mutant forms in the study from Chennai (55).It is 
planned to retest these children 6 months later to check for persistence of HBsAg 
positive status. Further testing by Polymerase Chain Reaction (PCR) amplification and 
HBV DNA sequencing for identification of mutants was not done due to lack of 
cryopreserved specimens and high costs involved. 
6.6.4 Risk factors for Vaccine failure 
The most significant risk factor for immunization failure was the HBeAg positive status 
of mothers (RR was 5.8; 95% CI: 1.58-21.11) for infection among children greater than 
two years. HBV DNA  is another significant risk factor for transmission of infection, 
with a study from Taiwan showing odds ratio for carrier state among children born to 
HBeAg negative mothers to be 19.2 (95% CI: 2.3-176.6) and a significant increase in 
odds ratio for HBsAg carrier state among children born to HBeAg positive mothers as 
well(28). This could not be studied in the present study in CHAD as the samples were 
not cryopreserved. The type of delivery (vaginal or Caesarian Section) was not a 
significant risk factor for the development of HBsAg among the children. A recent 
meta-analysis of randomized controlled trials showed that elective caesarian sections 
were protective although the evidence was not convincing due to a lack of good quality 
trials (36).  
6.6.5 Seroprotection among the immunized children 
 
The different vaccine schedules are known to produce different levels of antibody to 
HBsAg. Accelerated schedules which incorporate a birth dose (e.g. birth,1 and 2 
months) achieve lower final antibody levels compared to those where the second and 
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third doses are further apart which was also seen in the present study among children of 
all ages except those between 6-12 months (42,43).  
The data from the present study showed that the sero protection rate (anti HBs more 
than or equal to 10 mIU/ml) was 92.4% among children between 6-24 months of age 
which is similar to rates found in other Indian studies(39). The Geometric Mean Titre 
(GMT) of anti HBs for children aged 6 to 12 months was 345.9 mIU/ml which was also 
comparable to data available from other Indian studies (58).  
6.7 Vaccine efficacy 
 
Various studies have calculated the vaccine efficacy of Hepatitis B vaccine when used 
as post exposure prophylaxis to prevent perinatal transmission to be 70-95% (5,7,26).Our 
study showed the vaccine efficacy to be 68% in preventing HBsAg infection among 
children who received three doses of the vaccine according to standard schedules.  
  
6.8 Number Needed to Screen 
 
Assuming that the rate of vertical transmission rate to newborns is 18.6% (17) and the 
rate of chronic infection at one year to be 90% of this rate, the rate of Hepatitis B 
carriers would be 17%. The rate of transmission of HBsAg infection to vaccinated 
children in the present study was 5.4% and vaccine efficacy 68%.The Absolute Risk 
Reduction was 11.6% and the Number Needed to Treat (NNT) was 8.6. This implied 
that 8.6 children would have to be vaccinated to prevent one child from becoming a 
carrier. 
The Number Needed to Screen was 688 (64). In order to prevent one child from 
acquiring Hepatitis B infection from an infected mother, 688 antenatal women would 
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have to be screened in a program of selective immunization for children born to HBsAg 
positive mothers. 
 
6.9 Cost of preventing one case of Vertical Transmission 
The unit cost for preventing a single child born to an infected mother from becoming 
HBsAg positive was calculated assuming different strategies.  
1. Strategy of screening for Hepatitis B surface antigen and administering vaccine to 
children born to mothers who are Hepatitis B positive. Table No 16 shows the cost of 
preventing one case of perinatal transmission of HBsAg from infected mothers to their 
children. This was excluding the costs of counseling and direct non medical costs such 
as travel to place of testing/immunization. 
 
Table No. 16 Selective immunization strategy (administering vaccine alone) 
 
 Number Unit Cost  
(Indian Rs.) 
Total cost 
Cost of testing for 
HBsAg (Hepacard) 
688 (number 
needed to screen) 
30 20,640 
Cost of 3 doses of 
the vaccine  
 8.6 (NNT) 60 x 3 (doses) 1,548 
Total   Rs 22,188 
 
 
2. Strategy of screening for Hepatitis B surface antigen, followed by HBeAg for HBsAg 
positive mothers; administering vaccine to children born to mothers who are Hepatitis B 
positive and additional Hepatitis B immunoglobulin if the mother is HBeAg positive. 
Table No 17 shows the cost of preventing one case of HBsAg infection by this strategy. 
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Table No. 17  Selective immunization (vaccine and immunoglobulin) 
 
 Number of 
individuals 
Unit Cost  
(Indian Rs.) 
Total cost 
Cost of testing for 
HBsAg (Hepacard) 
688 tests (number 
needed to screen) 
30 20,640 
Prevalence of 
HBsAg 
1.25% of 688 = 8.6 
women 
  
Prevalence of 
HBeAg 
16.3% of 8.6 = 1.4 
women 
  
Cost of testing for 
HBeAg 
8.6 women 485 4,171 
Cost of 3 doses of 
the vaccine  
 8.6 (NNT) 60 x 3 (doses) 1,548 
Cost of hepatitis B 
immunoglobulin 
1.4 children 4800 6,720 
Total   33,079 
 
 
3.  Strategy of universal immunization starting at birth followed by two doses. 
 
Table No 18 shows the cost of universal immunization without antenatal testing, for the 
688 children born to the women who would have to be screened in the above strategies. 
 
 
Table No. 18 Cost of Universal immunization  
 
 Number of 
individuals 
Unit Cost (Indian 
Rs) 
Total cost 
Cost of 3 doses of 
the vaccine  
 688 children  60 x 3 20,640 
 
The present study did not show much difference between the costs of preventing one 
HBsAg positive carrier among the children born to Hepatitis B positive mothers by 
selective or universal immunization strategies. Studies worldwide have shown that 
universal immunization was more cost effective than selective immunization (8,68). 
However in view of the difficulties involved in administering the birth dose to all 
newborns due to lack of hospital deliveries and a large proportion of institutional 
deliveries occurring in low level health facilities, selective immunization may be a more 
71 
 
feasible alternative strategy of reducing Hepatitis B transmission until such a time when 
institutional deliveries become commoner in PHCs where the vaccine is also stored.  
The current strategy of the government of India of universal immunization starting at 6 
weeks would be ineffective in tackling vertical transmission. An expenditure of Rs. 525 
crores is also difficult to justify, given the low prevalence of HBsAg (1.25%) from our 
community based study as well as similar findings from other studies (65). 
Until the time when the strategy of universal immunization at birth (without antenatal 
screening) is possible, the option of selective immunization of infants born to carrier 
mothers (with the vaccine alone) can be considered in areas where the rate of 
institutional deliveries is reasonably high. A combined strategy of selective 
immunization commencing at birth, for children born to HBsAg positive mothers and 
universal immunization of other children along with the routine immunization schedule, 
would prevent both vertical as well as early childhood transmission.  
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                                   7. LIMITATIONS OF THE STUDY 
 
As the study was done five years after the program had started, the children were 
followed up at different ages, with some being over 5 years at the time of testing. The 
children who were HBsAg positive were also between 15-64 months, thus making it 
possible that some of them may have escaped perinatal transmission and acquired the 
infection horizontally due to an inadequate immune response. In order to evaluate 
vertical transmission alone HBsAg status of children born to infected mothers should 
have been checked at an earlier age before there could be chances of having acquired 
the infection horizontally. Analysis of cord blood for IGM anti HBc would have helped 
to make the diagnosis of infection acquired in-utero, against which immunization does 
not work. 
The follow up rate was only 67% for permanent residents, 53% for temporary residents 
from the service area and 30% for women who had registered at CHAD, although 
attempts were made to contact all of them. 
Detectable maternal HBV DNA which has been shown to be a significant risk factor for 
perinatal transmission could not be studied as the samples had not been cryopreserved 
and the costs involved were high. DNA extraction and sequencing to study mutant viral 
forms also could not be done due to the high costs. 
Prevalence of HBsAg infection among unvaccinated children could not be calculated 
from the study as none of the children available for serological testing were totally 
unvaccinated. Cost calculations were only analyzed with respect to the service provider 
and did not include the cost for the family in attending counseling and immunization 
sessions.                           
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                        8. CONCLUSIONS AND RECOMMENDATIONS 
 
The CHAD program for the prevention of vertical transmission of HBsAg was 
successful in screening 93% of the pregnancies in the service area, which was one rural 
block in Tamil Nadu. The prevalence of HBsAg positivity among the antenatal women 
in the service area was 1.25 % (95% CI: 1.05%-1.45%) which falls into the category of 
low endemicity according to the WHO (3). Evaluation of the program showed coverage 
of 70% for immunization with three doses of the Hepatitis B vaccine on schedule, 
commencing at birth. The program was able to administer birth dose to 77% of children 
born to HBsAg positive mothers in the service area and three doses of the vaccine to 
94.8%.  
Presence of HBeAg in the mother was found to be significantly associated with 
immunization failure (RR of 5.8; 95% CI: 1.58-21.11). The seroprotection rate (anti 
HBs of at least 10 mIU/ml) of children between 6-24 months was 92.4%. The vaccine 
efficacy was found to be 68% which was similar to other studies (5,7). 
As the NNT was 8.6, this implied that 8.6 children would have to be immunized in 
order to prevent one case of vertical transmission. The NNS being 688, this was the 
number of women who would have to be screened in order to prevent one case of 
vertical transmission of HBsAg by a program of selective immunization.  
The cost of preventing one case of HBsAg infection among children born to HBsAg 
positive mothers was Rs. 22,188 by the selective immunization strategy and Rs. 20,640 
by universal immunization. Considering the fact that many deliveries occur in lower 
level health facilities without a cold chain even in places where the rate of institutional 
deliveries may be high, universal immunization may not always be feasible and 
selective immunization may be a viable alternative. 
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 Thus instead of completely omitting the birth dose as is being done under the current 
government program, it would be useful to administer the birth dose of the Hepatitis B 
vaccine to infants identified to be at risk for perinatal transmission and to make the 
vaccine available to other children along with the DPT vaccines, in states where 
universal immunization at birth is not feasible. In Tamil Nadu with a high proportion of 
pregnant women receiving antenatal care and a high rate of institutional deliveries, 
provision of the birth dose to all newborns seems to be a feasible intervention to prevent 
perinatal transmission of Hepatitis B. As there has been a move to increase deliveries 
occurring at primary health center rather than at health subcentres, the availability of the 
vaccine also should not be a hindrance as the vaccines are available at the Primary 
Health Centre level. It is hoped that the government would consider introducing the 
birth dose of the Hepatitis B vaccine in regions like Tamil Nadu where it would be 
feasible to do so. 
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                                                Annexure 1 
                                             Questionnaire 
 
A. Demographic details 
1. Name 
2. Age 
3. Village Antenatal No 
4. Hospital No/ID No. 
5. Date of Last child birth 
6. Obstetric score    G P L A  
 
B. Antenatal period 
 
1. When was blood collected for testing for Hepatitis B during your pregnancy? 
2. Was consent taken at the time of testing for Hepatitis B? Yes/No 
3. Did you understand why it was necessary to have yourself checked for Hepatitis B?    
Yes/No 
4. Did you receive adequate post test counseling after being informed that you were 
Hepatitis B positive? Yes/No 
5. Did you ever feel that confidentiality was not maintained by the health staff, causing 
you discomfort? Yes/No 
 
C. Details of delivery 
 
 Where did you have your last delivery? 
 
CHAD/ CMC Vellore/ Vellore Medical College/ Home/ other Health centre 
 
When did your child receive the first dose of Hepatitis B vaccine? 
1. Within the first 12 hours 
2. Within 24 hours of birth 
3. After 24 hours of birth 
 
Date of receiving first dose:- 
Date of receiving second dose:- 
Date of receiving third dose:- 
 
If any dose was not given, or given late, was there any specific reason for the delay? 
If your child has not been immunized for Hepatitis B at all, can you tell us why you 
chose not to get your child immunized? 
 
Checklist: 
 
Birth dose timing checked: Yes/No 
Immunization card verified: Yes/No 
Hospital’s immunization record checked: Yes/No 
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                                                             Annexure 2 
                                                             Consent form 
The Department of Community Health, CMC Vellore, (CHAD), is conducting a study 
on all the children, who were born to mothers whose blood tested positive for jaundice 
(Hepatitis B). 
During your antenatal period you were tested for Hepatitis B and HIV after being 
informed of the need for the same. You were then offered intervention with 3 doses of 
Hepatitis B vaccine, commencing at birth. 
 Some of you accepted the intervention and some of you chose not to do so.  
We now need to test your child and check whether the vaccine has protected your child 
from Hepatitis B. We also need to check if the virus has stayed on or been removed 
from the blood. 
This means that we will have to collect 5 ml of the child’s blood on which three tests 
will be done to obtain the above information. 
 
I, Mrs. ________________________, wife of Mr._______________________, having 
read/been explained the above, give my consent for including my child in the study and 
for giving blood for testing him/her for the above mentioned tests. 
 
Signature/Thumb impression 
 
 
Witness                                                               Date 
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Evaluation of a program for the prevention of vertical transmission of Hepatitis B in 
Kaniyambadi block and CHAD hospital 
 
Background:  
Hepatitis B is one of the few vaccine preventable causes of a cancer. A third of chronic carriers 
acquire infection through perinatal transmission. However immunization at birth is not a part 
of the newly launched government program. Community Health Department of Christian 
Medical College, Vellore has been running a program of antenatal screening and selective 
immunization of children born to HBsAg positive mothers. Other children receive Hepatitis B 
vaccine along with routine vaccines. 
Objectives:  
The primary objective was to evaluate the effectiveness of the program in preventing HBsAg 
among immunized children born to infected mothers. Secondary objectives included assessing 
the coverage for the immunization schedule commencing at birth, effect of maternal HBeAg 
on immunization failures as well as seroconversion to the vaccine series. 
Methodology:  
Evaluation of the program was done by assessing immunization coverage achieved, vaccine 
efficacy and seroconversion to three doses of the vaccine by following up of the children of 
HBsAg positive women.  
Results:  
The prevalence of HBsAg among antenatal women was 1.25 % (95% CI: 1.05%-1.45%).  The 
coverage for three doses of the vaccine on schedule including a dose at birth was 70%. Vaccine 
efficacy was 68% and seroconversion was 92.4 % in children aged 6-24 months. HBeAg was a 
significant risk factor for immunization failure.  
Conclusions: 
The prevalence of HBsAg was very low and a program of selective immunization is a feasible 
alternative to universal immunization. Coverage of immunization along with a birth dose was 
higher than the coverage achieved in the pilot areas under the government’s strategy of 
universal immunization starting at 6 weeks. This strategy of screening and vaccination can be 
used in places where the rate of institutional deliveries is low while states with a high rate of 
institutional deliveries can give immunization at birth to all children. 
 
